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 ABSTRACT 
Protein kinase CK2 (official acronym for casein kinase 2 or II) is a potent 
suppressor of apoptosis. In response to diverse apoptotic stimuli, molecular 
downregulation of CK2 or activity inhibition results in potent induction of cell 
death. CK2 downregulation is known to impact mitochondrial apoptotic circuitry 
but the underlying mechanism(s) remain unclear. In addition CK2 dysregulation 
has been reported in all the cancer types studied so far. However CK2 is also 
found to be elevated in benign proliferative conditions as well. Thus, it appears 
that some additional factors cooperate with CK2α to promote the oncogenic 
phenotype. In the present study by utilizing prostate cancer cell lines subjected to 
CK2-specific inhibitors (TBB & TBCA) which cause loss of cell viability, we 
have found that a key event preceding the orchestration of apoptotic events in 
response to inhibition of CK2 activity is a rapid loss of mitochondrial membrane 
potential (Δψm). Upon treatment of cells with the CK2 inhibitor TBB changes in 
mitochondrial membrane potential become apparent within 2h, i.e., significantly 
prior to evidence of activation of other apoptotic signals. Our results also suggest 
that alterations in Ca
2+ 
signaling may be involved in the CK2 mediated regulation 
of Δψm as well as mitochondrial permeability. We propose that a mechanism by 
which CK2 regulates apoptotic activity in cells is via its control of Δψm, which 
may represent a locus of early signaling for induction of cell death following loss 
of CK2 activity. 
Present study also reports the collaborative role of CK2 and NFkB in the 
pathogenesis of prostate as well as breast cancer. Our results shows that nuclear 
expression of CK2 and NFkB are strongly associated with each other and works in 
 collaboration with initiation of cancer phenotype (p=0.01). This finding is 
supported by the fact that we did not find this association in BPH samples (p=0.1). 
The two factors are also found to be strongly associated with the stage of the 
disease (p<0.00). We have observed similar results in breast cancer tissue 
specimens. Where CK2α appears to cooperate with NFkB in the pathogenesis of 
disease (p=0.03). Based on the present findings we suggest that combination of 
CK2 and NFkB can serve better in determining the prognosis of cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 1 
INTRODUCTION 
1.1 Cancer  
Cancer is a group of diseases characterized by uncontrolled cell division 
and growth. This unregulated growth may result in formation of malignant tumors 
which can invade to other parts of body. Cell division and apoptosis are normal 
physiological phenomenon, tightly regulated by many signals originating within 
and outside the cell. Cancer cells develop a sovereign state which is independent 
of all such signals. This results in deregulated growth and propagation, which if 
left un-attended can be fatal (Hejmadi, 2010). 
There are about 200 different types of cancers and according to world 
health organization and International Agency for research on cancer (IARC) there 
were 7.6 million deaths worldwide due to cancer (approximately 13% of the 
deaths) in 2008. This makes cancer the leading cause of death worldwide. This 
death rate is expected to increase in future and can mount up to 13.1 million 
deaths in 2030 (Globocan 2008, IARC, 2010) 
Advances in research and modern technology has resulted in better 
understanding of biological pathways and chemistry of normal growth as well as 
pathobiology involved in development of cancer and other such diseases. This 
increasing knowledge has laid the foundation of cancer biology as a separate 
specialized field. The modern cancer biology rests on the foundation that all 
normal mammalian cells share a common network, pathways and signaling 
 systems that control their fate of cell division, survival and death. These normal 
cells are altered to cancerous state due changes or disruption in signaling networks 
which can be at molecular, cellular or biochemical and genetic level, and there are 
infinite number of reasons for any particular cell that causes this disruption 
(Hejmadi, 2010) 
In order to explain the complexity of cancer and to answer the following 
vital questions like; how normal cell changes to cancerous state? How at cellular 
and molecular levels signals are disrupted? How many connections could be 
broken? Or is there any one circuit which is altered and is common to all cancer 
types? And how the neighboring cell and micro environment plays its role in 
development of mutant cancerous state? Douglas Hanahan and Robert Weinberg 
in 2000 proposed six common and simplified hallmarks or the acquired 
capabilities of most of the cancers which are as follows 
 Self-sufficiency in growth signals  
 Escaping apoptosis 
 Insensitivity to anti-growth signals 
 Sustained angiogenesis  
 Tissue invasion and metastasis 
 Limitless self-replicative potential (Hanahan and Weinberg, 2000) 
  
Fig1: Acquired characters of cancer cells. Most of the cancer cells acquire 
these characters due to alteration in one of the various signaling pathways. 
Adapted from (Hanahan and Weinberg, 2000) 
Research over the last decade has resulted in addition of two more hallmarks 
which are now added to this list of characteristics which is shared by most of the 
cancer types, these two new hallmarks are  
 Modifying or reprogramming energy/cellular metabolism 
 Evading immune system (Hanahan and Weinberg, 2011) 
 
 1.2 Casein kinase2 (CK2) 
CK2 is a highly conserved and ubiquitously expressed serine/threonine 
kinase, Protein kinase CK2 is a heterotetramaric holoenzyme with two catalytic 
(αα') and two regulatory (β) subunits and is expressed in variety of cells. Various 
functions have been associated with CK2 enzyme activity including cell growth 
and proliferation (Guerra and Issinger, 1999, Tawfic et al., 2001, Ahmed et al., 
2002, Pinna, 2002, Litchfield, 2003). Cells with high mitogen activity have shown 
elevated expression levels of CK2 including many cancer cells (Stalter et al., 
1994, Yenice et al., 1994, Tawfic et al., 2001). Enforced over expression of CK2 
in transgenic mice resulted in T-cell lymphomas (Seldin and Leder, 1995) and 
breast cancer (Landesman-Bollag et al., 2001a).  In many solid tumors 
dysregulated activity of CK2 has been observed and linked to growth-promoting 
functions as well as to apoptotic suppression activity, assisting tumors to attain a 
resistant stage against the radiation and anti- cancer drug treatments. 
The anti-apoptotic aspect of CK2 activity may be of prime importance in 
prostate cancer, as it has been shown previously that as compared to proliferation 
dysregulated apoptotic activity seems to play more important role in the 
pathogenesis of the disease (Bruckheimer and Kyprianou, 2000, Kyprianou et al., 
2000). One of the main properties of CK2 is differential expression levels within 
different loci of cells in response to various stimuli.  Subjecting ventral prostate to 
altered androgenic stimulus demonstrated that elimination of androgenic signal 
resulted in the loss of phosphorylation as well as nuclear localization of CK2 
which was preceded by apoptotic induction in the epithelial cells of prostate. 
Whereas administration of androgen resulted in the nuclear shuttling of CK2 
 leading to growth and proliferation of prostatic epithelia (Guo et al., 1999b). 
Further evidence that CK2 has protected role against apoptosis was demonstrated 
by investigating the cancer cells that were treated with known apoptotic 
mediators, etoposide and diethylstilbestrol. Treatment of cells with these 
chemicals resulted in the rapid shuttling of CK2 to the nuclear compartment 
probably as the cells survival response.  This protective role of CK2 against 
apoptosis is further conformed by the fact that enforced expression of CK2 
preceding the treatment with etoposide or diethylstilbestrol strongly protected 
them against apoptosis (Guo et al., 2001) 
Although there is much evidence that CK2 is over expressed in prostatic 
cancer cells but over expression of CK2 is also associated with benign prostate. 
This fact implies that there must be some additional factors that work in co-
operation with CK2 to augment malignant phenotype. Thus the present study is 
designed to test the hypothesis that although both the phenotypes, benign and 
malignant over express CK2α there are some additional signals that are over 
expressed along with CK2 contributing to the development of cancer phenotype. 
One such signal may be NF-κB. The rational for the present study is provided by 
the fact that various studies have observed that both NF-κB and CK2 are 
constantly over expressed in prostate cancer pointing towards the fact that there 
might be a link between activity of these two factors in the development and 
pathogenesis of cancer. Another supporting evidence is the fact that NF-κB is one 
of the downstream targets of CK2 (Pinna, 2002).  
 Thus present study reports a correlation between the activities of the two 
signals in the prostate cancer cells but not in the benign cells, the new information 
 suggests a collaborative role of these molecules in the pathogenesis of the 
aggressive cancer phenotype. Thus combined together these two signals can act as 
prognostic markers and can serve as a better therapy target for treatment. 
In addition to prostate cancer tissue analysis, in the present study human 
breast cancer tissue samples are also assessed for same markers. This is an effort 
towards the identification of common signaling molecules that can be targeted in 
both cancer types. We suggest that research along these lines will be very cost 
effective. The present study supports the notion that many cancers can be treated 
by targeting one major signaling pathway. CK2 signaling pathway can serve this 
purpose. Future more research in this direction can lead to the development of 
common prognostic test and treatment protocol for the two major cancer types in 
both genders. This will be beneficial for the population in general as in long run 
we might be able to generate broad range anti-cancer drugs. 
Furthermore, the present study addresses the basic biology of the CK2. 
Much work has been reported showing that inhibition of CK2 results in the 
induction of apoptosis in prostate cancer cells. But the mechanism underplaying 
the induction of apoptosis is not fully understood. We have investigated what 
could be the earliest event in the chain of reactions that occurs after inhibition of 
CK2 by a chemical inhibitor. Present study reports that there is an immediate loss 
of mitochondrial membrane potential (Δψm) after inhibition of CK2. Loss of 
mitochondrial potential at such an early time point (2hrs) is a novel finding of this 
study and suggests rapid loss of Δψm as a primary event that triggers the 
mitochondrial apoptotic circuitry.  
 
 Chapter 2 
REVIEW OF LITERATURE 
2.1.1 Prostate gland 
 
 
Word prostate is derived from Greek word "prostates" which literally 
means "one who stands before", "protector" or "guardian". It is an accessory male 
reproductive gland in most of the mammals and is a compound tubuloalveolar 
exocrine gland. The main function of the prostate is to store and secrete milky 
white alkaline fluid that constitutes 20-30% of the semen volume along with 
spermatozoa. Spermatozoa ejaculated in prostatic fluid have better motility, longer 
survival and better protection of the genetic material (DNA) as compared to those 
which are expelled along with seminal vesicular fluid.  
Prostate, so called accessory reproductive gland is not of prime 
significance as far as male fertility is concerned but it has great impact on the 
quality of life because of its anatomical position. It surrounds the urethra just 
below the urinary bladder and prostate enlargement leads to a painful and 
distressful condition by blocking the urethra thus causing difficulty in urination.  
  
Figure 2: Position of prostate gland in male reproductive tract 
Source: Internet, 
http://medicalcenter.osu.edu/patientcare/healthcare_services/prostate_healt
h/anatomy_prostate_gland/Pages/index.aspx 
 
 
 
 
 
 
 
 
 
 2.1.2 Anatomy and histology 
 
 
Prostate is approximately a walnut size of gland in humans. Adult or 
mature prostate gland in man lacks the distinct lobular structure but still according 
to the classical anatomical definition of prostate gland it has zones (McNeal, 
1969). The four zones of prostate are central zone, periurethral transition zone, 
peripheral zone and fibromuscular zone (Timms, 2008). The site for the 
development of carcinomas and other disease conditions associated with prostate 
gland is the transition zone where as central zone is considered to be relatively 
free of carcinomas and hyperplasia.  Each grandular region has its particular 
structural and stromal characters. In general each zone has columnar secretory 
epithelium. Underneath this epithelium lies the basal cell layer with scattered endo 
and paracrine glands (McNeal, 1988)  
2.2 Prostate Cancer 
The most common anomalies associated with prostate are prostatitis, 
benign prostatic hyperplasia (BPH) and Prostate cancer (PCa). Of these prostate 
cancer is the most prevalent form of cancers in men of older age and even though 
much of recent advancement, prostate cancer still is one of the leading causes of 
cancer-related mortality and morbidity in men, with more than 186,000 people 
affected per annum, with a risk of 1:6 in a lifetime (Jemal et al., 2008).In Pakistan 
PCa is the most common malignancy (7.95%) in men (Zahur-ur-Rehman, 2000). 
The most prevalent test for the diagnosis of prostate function is prostate specific 
antigen (PSA) test and men with higher PSA values usually undergo biopsy for 
the evaluation of possible presence of cancer. Biopsies are followed by 
 histopathological Gleason scoring for grading of tumor. Although specific but 
PSA is not the most sensitive marker for the prediction of cancer progression. 
Upon conformed prostate cancer diagnosis, conventional management options are 
radical prostatectomy (surgical excision of the prostate), or brachytherapy 
(irradiation therapy through external beam or radioactive „„seeds‟‟ implantation). 
If the cancer is of advanced stage, androgen deprivation therapy usually either 
replaces or follows these treatment options, which initially results in regression of 
tumor cases the disease will reappear (Shen and Abate-Shen, 2010).  
2.2.1 Pathophysiology of Prostate Cancer 
Advanced age is the most significant risk factor associated with prostate 
cancer. Statistics shows that below the age of 40 years, 1 in 10,000 men have a 
chance to develop prostate cancer. This ration increases upto 1 in 7 men to 
develop cancer after the age of 60 years (Shen and Abate-Shen, 2010). Aging is 
the most well defined risk factor associated with prostate cancer but the exact 
molecular mechanisms during aging that lead to the development of cancerous 
state is still to be described and discovered. Many studies have shown 
modification in gene expression associated with aging. Genes that show alteration 
are associated with oxidative stress, inflammatory processes and cellular aging 
(Begley et al., 2005, Bavik et al., 2006, Bethel et al., 2009). Changes in the 
microenvironment of the cell/tissue are among the major contributors of cancer 
development. These microenvironment changes range from DNA damage due to 
accumulation of reactive oxygen species/free radicals leading to oxidative stress 
or inflammatory processes occurring in the prostatic stroma. Studies have linked 
infection and inflammation with prostate cancer development (Haverkamp et al., 
 2008, Klein and Silverman, 2008, Bardia et al., 2009) and have shown that 
recurrence of disease can be predicted by biochemical and expression analysis of 
some chemokines (Blum et al., 2008) 
Prostate appears to be exceptionally sensitive to oxidative stress. There are 
many contributing factors to this stress, deregulated hormones, infections, dietary 
habits and epigenetic changes leading to glutathione S-transferase (GSTP1) 
silencing. Correlational studies have provided evidence that initiation of prostate 
cancer is linked with oxidative stress. A study by Bostwick et al revealed reduced 
levels of antioxidant enzyme along with concomitant increase in the  8-oxy-
7,8,dihyro-29-deoxyguanosine (8-oxy-dG), additive oxidized DNA product in 
Prostatic intraepithelial neoplasia (PIN) and human prostate cancer (Bostwick et 
al., 2000) 
In addition to the microenvironment changes occurring at the tissue level, 
there are many molecular, signaling and genetic alterations that contribute towards 
the development and progression of prostate cancer.  The most well studied 
signaling pathway that is altered during prostate cancer initiation and progression 
is androgen receptor (AR) signaling. Normal growth and development of the 
prostate gland is androgens dependent process and high circulating androgen 
levels have also been proposed to be the major risk factor for prostate cancer 
(Hsing, 2001, Platz and Giovannucci, 2004).  
Extensive genetic studies and investigations have led to the discovery of 
various alterations in copy number as well as chromosomal rearrangements to be 
associated with prostate cancer initiation and progression. Comparative genomic 
 hybridization (CGH) analysis studies have discovered that loss and gain of 
chromosomal areas are associated with prostate cancer. These alterations include 
additions at 8q, whereas deletions at 3p, 8p, 10q, 13q and 17p of chromosomal 
areas have been reported to be associated with prostate carcinoma (Dong, 2001, 
Lapointe et al., 2007, Taylor et al., 2010). Many of these genetic modifications 
have also been observed in PIN and proliferative inflammatory atrophy (PIA), 
supporting the notions that these alterations led toward the cancerous 
genotype/phenotype (Shen and Abate-Shen, 2010). In addition many of the key 
genes involved in prostate homeostasis are mapped to regions which are most 
susceptible to the genetic alterations. The genetic alterations associated with 
prostate cancer are mapped to regions which undergoes gain and loss of copy 
number alterations for example at 8021 NKA3.1, PTEN at 10q23, gain of function 
or up regulation of MYC at 8q24 and loss at 10q23and 16q23 (PTEN) (Lapointe 
et al., 2007) 
 
  
 
Figure 3: Initation and progression of prostate cancer. Together are shown 
the processes involved and genes alteration that are most likely to be 
associated with each stage. Adapted from Shen and Shen (2000) 
  
2.3 Breast: The female mammary gland  
 
2.3.1 Anatomy and Histology  
 
Mammary gland or Brest is a modified form of sweat gland. Functional 
layer of breast consists of secretory epithelium surrounded by stroma. Each breast 
has 15-25 segments/lobes, lobular in shape that radialy covers the nipple. Each 
lobe consists of six ducts, lactiferous duct and lactiferous sinus, segmental 
collecting duct, subsegmental duct, ductile (terminal duct) and acini (terminal 
ductules). The glandular portion of ducts has terminal ductulobular units 
(TDLUs). These TDLUs are the main functional part of the breast and are most 
sensitive to hormone regulation. Thus most of the pathological conditions 
originate at this site.  Collecting ducts have multilayered columnar lining whereas 
lactiferous ducts and lactiferous sinuses are lined by squamous epithelium at their 
terminal portions (Bibbo and David, 2008) 
2.4 Breast Cancer 
 
Breast cancer is one of the leading causes of death in women. According to 
"World Cancer Report" International Agency for Research on Cancer, breast 
cancer accounts for 25% of all cancers in women, excluding skin cancer (non-
melanoma). Over all breast cancer has been rated at 5
th
 position among all cancer 
causing deaths, with 522,000 deaths in the years 2012. It is the most frequent 
cause of death among the women of developing countries (14.3% of total, 324.000 
deaths). Whereas in developed countries it is the second most frequent cause of 
death among women (15.4%, 198,000 total deaths) (Globocan 2012).  Pakistan 
has the highest rate of breast cancer incidence in south Asia with one out of every 
 nine women at risk of developing cancer at any stage of their life (WHO, IARC 
2012)  
Most commonly breast cancer develops from the inner lining of the ducts 
or from lobules (TDLUs) that supply milk to ducts (Sariego, 2010). Depending 
upon the site of origin breast cancer can be classified as ductal or lobular 
carcinoma. For early diagnosis and in time treatment breast cancer screening is 
highly recommended, but still there is an on-going debate on the pros and cons of 
regular screening. Once diagnosed, treatment options depend upon the stage and 
characteristic of disease. The possible treatment options includes surgical 
procedure, non-invasive medication like hormonal or chemotherapy, 
immunotherapy and/or radiation (Florescu et al., 2011). Depending upon each 
individual case, these treatment options may be carried out singly and/or in 
combination. Over all surgery provides the best beneficial results with very little 
chance of remission. Usually surgery is followed by multiple chemotherapeutic 
procedures to improve the prognosis of the treatment. Radiation therapy following 
the breast conserving surgery improves the overall survival and local relapse of 
the disease (Buchholz, 2009) 
2.4.1 Pathophysiology of Disease 
 
 Like all the other cancers, breast cancer is caused by the interaction 
between genetically susceptible host and the precipitating environmental factors. 
Such interactions results in an attainment of ability to avoid or escape from the 
apoptotic signals. Thus cancerous cells are protected from the death signals. These 
protective signals involved many pathways for example PI3K/AKT pathway, 
RAS/MAK/ERK pathway and many others. In normal cells these pathways are 
 turned on only when cell is in proliferative stage. When the need to divide further 
is over, there are many signaling molecules which turn these pathways off. In 
cancer there are mutations in genes which turn these protective pathways off, 
rendering them permanently “on”.  One such signaling molecule is PTEN, which 
turns off PI3K/AKT. Normally when the need to divide further is over and cell is 
ready to die PTEN turns off PI3K/AKT pathway. Mutated non functional PTEN 
protein is associated with breast cancer which leads to the permanently on 
PI3K/AKT pathway, thus cancer cell is unable to commit suicide 
(Yiannakopoulou, 2013) 
The other important pathway associated with breast cancer development is 
sex hormone-receptor signaling. These steroid hormones coordinately work with 
growth factors for cell proliferation.  Estrogen signaling pathway is known for a 
long time to be one of the most important risk factor associated with breast cancer. 
There is a dominant number of breast cancer patients that over express estrogen 
receptor (ER). Thus ER turned out to be one of the most important therapeutic 
targets (Higa and Fell, 2013) 
In addition to ER there are substantial amount of studies which indicate 
that androgen receptor (AR) is also over expressed by most of the primary breast 
cancer patients. AR is either over expressed along with the ER. In such cases AR 
can be more useful for prognosis. In addition there are studies which report AR 
over expression independent of the ER expression. Thus AR status alone can also 
serve as the prognostic marker and therapeutic target (Higa and Fell, 2013)  
Mutations in genes involved in DNA damage repair are also linked to the 
development of breast cancer. The most important genes reported in this scenario 
 are BRCA1, BRCA2 and p53. Escape from damage repair leads to the inheritance 
of erroneous DNA. Although mutation in BRCA1/2 increases the risk of breast 
cancer up to 60-80% in a life time but there are only 2-3% of all the breast cancer 
which show over-expressed BRCA1/2 (Begg et al., 2008). The other contributing 
factors may involve poor surveillance and failure to remove the malignant cells 
from the body (Kim et al., 2007). Abnormal signaling between epithelial and 
stromal cells (Haslam and Woodward, 2003) and over expression of leptin in the 
surrounding adipose tissue may increase cell proliferation and malignant cell 
growth(Jarde et al., 2011)    
2.5 Protein kinase CK2/Casein kinase II 
 
 
Protein kinase CK2 is an acronym for the for the previously misnamed 
casein kinase II, studies have shown that it does not have any role in 
phosphorylation of casein; protein from which it acquired its name (Lasa et al., 
1997). Protein kinase CK2 is a small family of kinases which have broad 
specificity and phosphorylate multiple substrates (Lozeman et al., 1990, Pinna, 
1990, Litchfield and Luscher, 1993, Allende and Allende, 1995, Lasa et al., 1997, 
Pinna and Meggio, 1997, Blanquet, 2000, Faust and Montenarh, 2000, Ahmed et 
al., 2002) 
 
2.5.1 General Structure and Enzymatic Characteristics of CK2 
 
 
CK2 is a highly conserved and ubiquitously expressed serine/threonine 
kinase. It is a heterotetramaric holoenzyme with two catalytic and two regulatory 
subunits and is expressed in variety of cells. Different isoenzymatic forms of 
 catalytic subunit have been reported in many organisms (Litchfield et al., 1990, 
Lozeman et al., 1990, Maridor et al., 1991, Glover, 1998, Xu et al., 1998). In 
humans, two isoenzymatic forms of catalytic α subunit are well characterized, i.e. 
CK2α (~42kDa) GeneID: 1457), CK2α' ((38kDa) (GeneID: 1459) and the third 
isoform, CK2α'' is also reported (Litchfield et al., 2001, Shi et al., 2001). In 
humans, regulatory subunit of CK2 exists in a signal form as CK2β (26kDa) 
(GeneID: 1460) but in other organisms isoforms of regulatory β subunit have also 
been identified. (Glover, 1998). In the quaternary heterotetrameric structure 
complex, CK2α subunit can exists either as identical dimer of CK2αα or CK2α'α' 
or non-identical complex of one CK2α and other CK2α' subunit (Gietz et al., 
1995). CK2 β dimers occupies the central position (Gietz et al., 1995, Boldyreff et 
al., 1996, Pinna and Meggio, 1997, Chantalat et al., 1999, Graham and Litchfield, 
2000, Canton et al., 2001, Niefind et al., 2001). This central position of the 
regulatory β subunit serves as a linker molecule to hold together the two catalytic 
α subunits. Formation of holoenzyme is a stimulatory signal for the kinase activity 
rather than inhibitory (Trembley et al., 2009). After the discovery of the CK2 
many efforts were made to discover the minimal consensus sequence that is 
required for phosporylation by CK2. Systematic studies by Pinna et al and others 
made it possible to define such a sequence as Ser-Xaa-Xaa-Acidic, where Glu, 
Asp, pSer or pTyr could be the acidic residue (Pinna, 1990, Ahmed et al., 2002). 
Identification of this consensus sequence proved to be beneficial and greatly 
facilitated the identification of new potential substrates for CK2. At the same time 
this delineation poses some limitations. There are studies that have reported the 
sites efficiently phosphorylated by CK2 but they do not correspond to this 
 consensus sequence for example anti-tumor p53 has Ser
392
 which is not 
phosphorylated by this sequence (Meek et al., 1990). On the other hand there are 
sites which do have this minimal consensus sequence but they are not efficiently 
phosphorylated by CK2. Thus there may be additional sites within the sequence 
that modulate efficient phosphorylation (Meggio et al., 1994).  
 
 
 
 
 
Figure 4: Tetrameric CK2 structure illustrated by ribbon diagram. Adapted from 
(Litchfield, 2003) 
 
2.5.2 CK2 regulation in cells 
 
 
Over the years there has been much debate, controversy and excitement 
over how CK2 is regulated within the cells. In the tissue and cells extracts, CK2 
has been found active even in the absence of any stimulation. This finding led to 
the conclusion that CK2 is a constitutively active enzyme (Litchfield, 2003, 
Litchfield et al., 1994). Many studies have reported activation of CK2 in response 
 to a variety of stimuli (Litchfield et al., 1994), as yet there is no consistency in 
these studies and it is difficult to draw precise and concise decision regarding the 
regulation of CK2 within the cells. It appears that there is an array of diverse 
mechanisms responsible for the physiological regulation of CK2. In general few 
mechanisms that are reported to regulate CK2 activity are controlled assembly and 
expression, covalent modifications and protein-protein interactions and 
interactions with non-protein molecules. In addition studies reporting the high 
resolution structure of CK2 have reported presence of ATP binding site in one of 
the catalytic subunit. This information points that some ATP dependent regulation 
of CK2 might also exist (Litchfield, 2003)    
 
 
Figure 5: Plausible mechanisms of regulation of CK2 within the cell 
(Litchfield, 2003)  
 
 
 2.5.3 Cellular Functions of CK2 
 
 
CK2 is involved in multiple cellular processes. Role of CK2 in cell 
proliferation, growth and regulation of gene expression has been known for a long 
time (Ahmed, 1999, Guerra and Issinger, 1999, Ahmed et al., 2000, Tawfic et al., 
2001, Pinna, 2002, Litchfield, 2003). Evidence has shown that life is not possible 
without CK2 and attempts to generate CK2 knock down animal model has met 
with failure (Padmanabha et al., 1990, Buchou et al., 2003).  A large number of 
proteins have been identified as a substrate of CK2. Many of these proteins are 
involved in the growth related function. For example proteins and factors 
implicated in synthesis of nucleic acid  and protein, transcription factors, tumor-
suppressor and oncogenes ,signal transduction proteins and viral proteins (Guerra 
and Issinger, 1999, Tawfic et al., 2001, Pinna, 2002). Studies have shown 
involvement of CK2 in progression of cell cycle (Lorenz et al., 1999, Wang et al., 
2003). Dynamic association between CK2 and nucleosomes has also been 
reported and this association depends upon the transcriptional state of the 
nucleosomes (Guo et al., 1998, Guo et al., 1999a). Furthermore, genome wide 
analysis of gene expression has shown a universal role of CK2 in chromatin 
remodeling (Barz et al., 2003). Initially, it was believed that CK2 status is the 
reflection of the proliferative state of the cell. But in cancer cells elevated CK2 
also relates to the extent of dysplasia in cell in addition to the proliferative index 
of cancer (Faust et al., 1996, Ahmed et al., 2000, Faust and Montenarh, 2000). 
Furthermore tissues like brain and testis have very high levels of CK2 (Guerra and 
Issinger, 1999, Blanquet, 2000), suggesting that CK2 might be involved in other 
functions within these tissue. Studies investigating the functional capabilities of 
 CK2 reported an additional key role of CK2 as suppressor of apoptosis (Ahmed et 
al., 2002, Litchfield, 2003). Although it was reported earlier that removal of 
androgen resulted in loss of CK2 from the nuclear compartment and induction of 
apoptosis in prostate tissue, while androgen administration reverted back 
phenomenon (Ahmed et al., 1993, Tawfic and Ahmed, 1994, Tawfic et al., 1996), 
direct evidence of CK2 as an anti-apoptotic agent came from the studies by 
Ahmed and his team, which showed that cells over expressing CK2 showed a 
protection against chemically induced apoptosis by diethylstilbestrol and 
etoposide (Guo et al., 2001). Not just the chemically induced apoptosis, CK2 has 
been shown to affect the death receptor mediated apoptosis as well. Cells over 
expressing CK2 shows protection from the apoptosis induced by death receptor 
ligands such as, tumor necrosis factor α (TNFα), Fas ligand (FasL) and TNF-
related apoptosis-inducing ligand (TRAIL), while its down regulation promotes 
cell death via death receptors.(Wang et al., 2005a). Furthermore, studies have 
reported that CK2 is capable of blocking the apoptosis induced by radiation and 
heat shock (Gerber et al., 2000, Davis et al., 2002, Yamane and Kinsella, 2005). 
An additional role of CK2 as a facilitator in DNA repair has also been reported. 
CK2 facilitates in the repair of single stranded chromosomes (Loizou et al., 2004). 
Thus taken together all this data suggests a global role of CK2 in protection 
against apoptosis in addition to its role in cell growth and proliferation (Davis et 
al., 2002) 
2.5.4 Intracellular CK2 Dynamics 
 
An important aspect of CK2 biology and function is its location within the 
cell. CK2 distribution undergoes rearrangement to various compartments of the 
 cell in response to variety of stimuli. This dynamics in distribution was first 
demonstrated in response to the androgen or growth factor stimulation in prostate. 
Studies showed that CK2 is translocated to the nuclear compartment in response 
to the androgenic stimulation and there was a rapid loss of nuclear CK2 upon 
removal of this stimulus (Ahmed et al., 1993, Tawfic and Ahmed, 1994, Tawfic et 
al., 1996). Further work along this line suggests that shuttling of CK2 to various 
compartments of cell in response to various growth promoting stimuli is a 
common downstream reaction of a cell (Guo et al., 1999b). Furthermore CK2 has 
a potential to associate dynamically and integrate into a multimolecular functional 
complex (Filhol et al., 2004). These dynamic modulations of CK2 in response to 
the up regulation or down regulation of enzyme are of great of interest. As 
intracellular location of CK2 is the reflection of cell growth and or death, 
especially the nuclear matrix associated CK2.      
 
2.5.5 Role of CK2 in Oncogenesis 
The relationship of CK2 with cancer has been long recognized and CK2 
has been found to be uniformly over expressed in all the cancers studied so far 
(Tawfic et al., 2001, Guerra and Issinger, 2008, Trembley et al., 2009). Important 
observation regarding this fact is, CK2 is elevated at protein level and not at the 
level of message (Tawfic et al., 2001).  Among many distinct traits, deregulated 
growth and proliferation as well as deregulated apoptotic pathway are the two 
consistent features of cancer cells (Hanahan and Weinberg, 2000, Evan and 
Vousden, 2001). CK2 has been long known to effect the cell proliferation both in 
normal and cancerous cells, the fact that now CK2 is also liked to the apoptotic 
machinery and has been demonstrated as a potent anti-apoptotic agent, provides 
 crucial clue that connects the kinase with cancer (Ahmad et al., 2008). CK2 is 
elevated both in normal proliferative cells and cancer cells. It is suggested that all 
cells have some basic levels of CK2 which they maintain. These basal levels of 
CK2 are crucial to the homeostasis of cell (Trembley et al., 2009). Cancer cells 
show addition to CK2 (Ruzzene and Pinna, 2010). During normal physiological 
condition each cell tend to resist even the slight change in the CK2 levels and does 
not allow even minor up and or down regulation of kinase. Cancer cell acquire 
new elevated basal levels of CK2 and ensures to maintain these new levels just 
like a normal cell, although now cells have deregulated and elevated CK2 levels 
as compared to the normal counterparts (Trembley et al., 2010b) This idea is 
supported by the fact that all efforts to generate stable forced over expression of 
CK2 are unsuccessful in both normal and cancer cells (Yu et al., 1999, Wang et 
al., 2003). 
It is apparent from the above mentioned discussion that CK2 is not 
oncogenic by itself. But during the process of cell transformation, occurs a 
significant dysregulation in the CK2 levels leading to its altered basic status. This 
change imparts the oncogenic capability to cells (Trembley et al., 2009). This 
view is supported by the studies on experimental animal, for example there is a 
considerable increase in the incidence of leukemia and lymphoma in transgenic 
mice overexpressing CK2 combined with c-myc or Tal-1(Kelliher et al., 1996, 
Landesman-Bollag et al., 1998, Landesman-Bollag et al., 2001b, Channavajhala 
and Seldin, 2002). Mouse model of breast cancer, expressing CK2 under the 
control of MMTV-LTR shows several features similar with human cancer 
(Landesman-Bollag et al., 2001b). In each experiment only the slight over 
 expression of CK2α transgene was enough to evoke ongonenic potential in mice 
model.  These observations suggest that oncogenic potential of CK2 is coined 
with the alterations in activity of additional oncogenic molecules within the cell. 
This notion is supported by the studies showing that stability of c-myc with in the 
cell is influenced by CK2 (Channavajhala and Seldin, 2002) as well as CK2 
enhances Wnt signaling in tumorigenesis (Seldin et al., 2005)  
 
2.5.6 Interaction of CK2 with other Signaling Molecules in Cancer 
 
Taken together, all the data available on CK2 suggests that it is involved in 
multiple biochemical and cellular processes.  Thus there are more than 300 
substrate of CK2 identified so for, which carry out all these processes. To 
accomplish all the tasks assigned, CK2 interacts with a large variety of molecules 
and all these molecules are part of complex crosstalk and signaling networks 
(Tawfic et al., 2001, Meggio and Pinna, 2003, Wang et al., 2006b, Ahmad et al., 
2008, Guerra and Issinger, 2008). CK2 being ubiquitous enzyme, present in both 
normal and malignant cells, it is believed that activity of CK2 depends upon the 
oncogenic state of the cell, and or its activity towards certain substrate may be 
altered so as to support the biological processes of malignant cells (Guerra and 
Issinger, 2008). 
Dysregulated CK2 leads to dysregulation of many other signaling 
networks which in turn leads to development of cancerous phenotype. Most 
important and well established CK2 signaling targets related to cancer are; CK2 
interactions with RNA polymerase I, II and III protein complex (Cardenas and 
Gasser, 1993, Ghavidel and Schultz, 2001, Johnston et al., 2002, Panova et al., 
 2006). Many studies have shown a global role of CK2 in chromatin remodeling 
and transcription regulation (Guo et al., 1998, Guo et al., 1999a, Barz et al., 2003). 
CK2 is associated with many pre mRNA transcription factors and is known to 
affect the activity of many splicing factors thus altering the gene expression 
(Ghavidel and Schultz, 2001, Johnston et al., 2002, Cabrejos et al., 2004, Lewis et 
al., 2005, Bierhoff et al., 2008, Trembley et al., 2009). CK2 is also known to 
affect transcription via steroid hormone receptor signaling. This action of CK2 is 
well documented in response to androgen signaling in prostate (Götz et al., 2007). 
Studies have shown that in breast CK2 phosphorylate β catenin thus regulates the 
Wnt signaling (Landesman-Bollag et al., 2001b, Seldin et al., 2005). Similarly 
CK2 has been shown to be involved in overexpression of NFkb in through 
aberrant activation of IKKs in breast cancer PTEN and Akt have been shown to 
play a crucial part in cancer development. CK2 is involved in the phosphorylation 
and stability of PTEN (Torres and Pulido, 2001, Vazquez et al., 2001, Miller et 
al., 2002, Torres et al., 2003). Akt is activated upon phophorylation, Akt kinases 
phophorylates it at many sites, but CK2 is also known to phophorylate Akt at Ser-
129 resulting in it‟s over activation (Di Maira et al., 2005). Role of p53 has been 
well established in cancer and CK2 is involved in the phosphorylation of p53 
aswell. The association of p53 and CK2 and their link with cancer development 
has been studied extensively (Meek et al., 1990, Prowald et al., 1997, McKendrick 
et al., 1999, Schuster et al., 2001). 
In addition to all the above mentioned signaling networks affected by 
dysregulated CK2 in cancer, CK2 has also been shown to have a global role in 
regulating apoptotic machinery of the cell.  Various downstream targets of the 
 apoptotic pathway regulated by CK2 involves, Bad (Klumpp et al., 2004), Bid 
(Desagher et al., 2001, Olsen et al., 2006) fas1 (Olsen et al., 2003), Max 
(Krippner-Heidenreich et al., 2001), Bcl2 family proteins (Wang et al., 2006a, 
Wang et al., 2008), inhibitor of apoptosis proteins (IAPs) together with surviving 
(Tapia et al., 2006, Wang et al., 2008), caspase-inhibiting protein ARC (Li et al., 
2002) and caspase 2 (Shin et al., 2005). 
2.5.7 CK2 and Mitochondrial Apoptotic Pathway 
Bcl2 family protein directly affects the mitochondrial apoptotic machinery. 
BclxL membrane of Bcl2 family is a transmemebrane protein and is an anti-
apoptotic agent that affects the mitochondrial apoptotic machinary. CK2 has been 
shown to activate BclxL via NFkb activation, activated BclxL sequesters 
truncated Bid (tBid) thus inhibiting the mitochondrial apoptotic pathway (Ravi 
and Bedi, 2002). Stimulated tBid activates mitochondrial outer membrane 
permeabilization (MOMP) and release of apoptotic factors from mitochondria 
(Brenner and Kroemer, 2000). Over expression of CK2 provides protection 
against death pathway initiated by the caspase-8, this is achieved via delay in the 
cleavage of Bid. This protection is lost by the chemical inhibition of CK2 
(Hellwig et al., 2010). Moreover studies have shown that CK2 inhibition also 
reduces the FLICE-inhibitory protein (FLIP) expression and favors its degradation 
by proteosome complex. Decreased expression of FLIP favors the initiation of 
caspase -8 pathways, upon activation by the death receptor ligands, resulting in 
the initiation of mitochondrial death pathway via activation of tBid (Llobet et al., 
2008). Chemical inhibition of CK2 also affects MOMP, by promoting the 
translocation of tBid and Bax to mitochondria (Rehm et al., 2009).  As a whole 
 data suggests that elevated levels of CK2 in tumor cells reduces the cleavage of 
Bid, thus preventing the initiation of mitochondrial death machinery and favors 
carcinogenesis.  
Bax a pro-apoptotic member of BcL2 family is activated in cytoplasm and 
then translocated and incorporated into the outer mitochondrial membrane 
(OMM). This incorporation serves as positive signal for MOMP resulting in the 
release of apoptotic factors from inter membrane space (Ahmad et al., 2004). 
Hydrogen peroxide has been shown to activate Bax via it‟s acidification in 
cytosol. This phenomenon is observed in studies where H2O2 is produced in 
response to the drug induced apoptosis. This acidification is a strong signal for the 
translocation of Bax to OMM. Acidified Bax, when translocated to OMM initiates 
the formation of pores in the membrane. This serves as a positive feedback for 
more production of H2O2 leading to the oxidative damage and destabilization of 
OMM (Asumendi et al., 2002, Ahmad et al., 2004). Studies have shown that 
inhibition of CK2 results in the increased production of H2O2 and induction of 
apoptosis (Ahmad et al., 2004, Ahmad et al., 2006). Apoptosis induced by the 
inhibition of CK2 can be blocked by the pretreatment with catalase, H2O2 
scavenger (Ahmad et al., 2004). These studies provide additional evidence that 
CK2 over expression in cancer cells provides them protection against apoptosis. 
Over expressed CK2 blocks the mitochondrial mediated apoptosis by inhibiting 
the production of H2O2, a key mediator of outer mitochondrial membrane 
potential (OMMP) (Hanif and Pervaiz, 2011) 
 
 
 2.5.7 Targeting CK2 for Cancer Therapy 
 
Ahmed and his team for the first time proposed that CK2 can serve as a 
target for cancer therapy. This suggestion was based on many characteristics of 
CK2, most important being its dual action affecting the cell proliferation and 
growth as well as a potent anti-apoptotic agent (Unger et al., 2004, Ahmad et al., 
2005, Guerra and Issinger, 2008). In the field of cancer research aiming to 
discover the treatment or drug for the disease, the eventual goal is to eliminate the 
tumor cell completely from within the host such as to achieve a disease free state. 
Thus by principle such a gene should be targeted that is indispensable for life so 
that its inhibition does not end up in the resistance towards treatment and tumor 
cells are not able to avoid death by adopting any alternative path of survival 
(Wang et al., 2006b, Trembley et al., 2009). CK2 can serve as potential target for 
this purpose. Earlier studies have shown that targeting protein kinases not vital for 
life, limits their effectiveness in the curing the disease completely (Cho-Chung, 
1996, Cho et al., 2002, Gleave and Monia, 2005). CK2 does not pose this problem 
as it has been shown to be vital for cell survival. In addition being vital for life, 
following features of CK2 makes it an important potential target for cancer 
therapy.  
CK2 has been shown to respond to various mitogenic stimuli under 
various conditions within the cells (Ahmed, 1994, Ahmed, 1999, Tawfic et al., 
2001, Yu et al., 2001, Ji et al., 2009). Multiple pathways such as angiogenesis, 
inflammation and drug efflux, which are helpful in the elimination of cancer, are 
affected by the CK2 downregulation (Kramerov et al., 2006, Di Maira et al., 2007, 
Kramerov et al., 2008, Singh and Ramji, 2008). Pathological state of tumor is 
 being reflected by the deregulated increase in the expression level of CK2. 
Downregulation of CK2 not only affects the growth and proliferation of cancer 
cells but also the apoptotic pathway, this makes the CK2 double edged sword for 
cancer cells (Guo et al., 2001, Barz et al., 2003, Slaton et al., 2004, Ahmad et al., 
2005, Wang et al., 2005b, Ahmad et al., 2008, Guerra and Issinger, 2008, 
Trembley et al., 2009). Last but not the least CK2 is indispensable for life, and so 
far there is no redundant pathway that can compensate for the CK2 
downregulation (Padmanabha et al., 1990, Buchou et al., 2003, Lou et al., 2008, 
Seldin et al., 2008).  
Keeping in view above mentioned suitable characters of CK2 as potential 
target for cancer therapy, many approaches are tested for effective downregulation 
of CK2. Among these are, use of small molecule chemical inhibitors (Zien et al., 
2003, Mishra et al., 2007, Anderes et al., 2009, Battistutta, 2009, Pinna and 
Allende, 2009, Prudent and Cochet, 2009, Sandholt et al., 2009), blocking of CK2 
phosphorylation sites of substrate by the using peptide inhibitor (Solares et al., 
2009). Use of small interfering RNA (siRNA) for down regulating CK2 at 
molecular level (Wang et al., 2001, Slaton et al., 2004, Unger et al., 2004, Ahmad 
et al., 2005, Guerra and Issinger, 2008, Trembley et al., 2009, Trembley et al., 
2010a). The main point of concern in targeting CK2 for cancer therapy is the host 
toxicity. To this end it has been shown that relative to cancer cells, normal cell 
shows some resistance towards the induction of apoptosis upon downregulation of 
CK2 by chemical inhibitors and or antisense CK2α oligodeoxynucleotide (ODN) 
(Ahmed, 1994, Slaton et al., 2004). In spite of this, efforts should be made to 
develop an approach that effectively downregulates CK2 only in cancer cells 
 while minimal or no effect on the normal cells. Use of chemical inhibitors 
(Anderes et al., 2009) or blocking the phosphorylation sites by peptides (Solares et 
al., 2009) is not a protective approach in vivo. Their utilization in translation 
medicine is still to be tested with regard to the potential of host toxicity and 
resistance which will ultimately determine their efficacy in treating the disease in 
vivo.  
Ahmed and his team (2010) has proposed a novel method for targeted drug 
deliver to the cancer cell and sparing the normal cells. They have used a sub-50 
(less than 50 nm in size) tenfibgen (TBG) nano-capsule for the delivery of 
condensed CK2 antisense siRNA or small molecule inhibitor specifically to the 
target cancer cells (Trembley et al., 2012). Further work is required and is in 
progress to determine the success of this approach. If successful this technique has 
a clear advantage over all the other approaches as probably it will be extremely 
efficient in death induction in tumor cells only and can also overcome the drug 
resistance issues of cancer treatment (Trembley et al., 2010b, Trembley et al., 
2012) 
2.6 Rationale for Study 
• The rationale behind this hypothesis is; downregulation of CK2 resulted in 
upregulation of Bax and downregulation of Bcl-2 and Bcl-xL accompanied 
with release of cytochrome c. [Wang et al., 2005a, 2006]. Further; 
downregulation of CK2 activity or expression in prostate cancer cells for 
6–24 h resulted in production of H2O2 hinting that this may initiate 
apoptotic signaling under these conditions [Ahmad et al., 2006] 
 • The rationale is that in various studies it has been observed that NF-кB and 
CK2 are consistently elevated in prostate and breast cancer raising the 
possibility that there may be a link between the two activities in relation to 
the pathogenesis of cancer. Another supporting rationale is that NF-кB is a 
downstream target of CK2α 
2.7 Hypotheses 
The hypotheses pursued in this study were: 
1. The primary trigger(s) for the initiation of apoptotic signaling upon CK2 
downregulation involves the mitochondrial apoptotic circuitry 
2. CK2α overexpression in development of the cancer phenotype is 
associated with a concomitant overexpression of additional signals. One 
such signal may be NFкB 
 
 
 
 
 
 
 
 Chapter 3 
MATERIALS AND METHODS 
3.1 Material and Reagents 
BAPTA, CalBiochem Cat#196419, Bovine Serum Albumin (BSA)  Thermo 
Fisher, cat# SH30574.01)-2%stock. Dissolve in 500ml Ham‟s F-12s, Cell titer 96 
Aqueous-One solution, Promega, Cat# G3580,  Coomassie Protein Assay 
reagent, ready to use coomassie blue G-250 based reagent by thermo scientific 
(Prod# 1856209). Catalase from bovine liver, Sigma Aldrich, Cat# C1345, 
Carbonyl Cyanide m-Chlorophenylhydrazone (CCCP) Calbiochem:  In all 
experiments CCCP was used at concentration of 10uM/ml or otherwise 
mentioned, Dulbecco’s Phosphate Buffer Saline (DPBS 1X) Gibco by life 
technologies Ref# 14190-136, Fetal Bovine serum (FBS) Atlanta Biologicals, 
tetrachloro-1,1',3,3' tetraethylbenzimidazolylcarbocyanine iodide JC-1 Life 
Technologies: In all experimental settings JC-1 was used at concentration of 
5ug/ml or otherwise mentioned, Matrigel BD matrigel matrix Cat# 354234, 
Oligomycin: Sigma Aldrich, Cat # 04876. In all experiments oligomycin was 
used at a concentration of 2.5ug/ml, or otherwise mentioned, 4,5,6,7-
tetrabromobenzotriazole, TBB (Casein Kinase-2 Inhibitor 1, Calbiochem, 
Cat#218697, tetrabromocinnamic acid (TBCA) (Casein Kinase-2 Inhibitor),  
Calbiochrm Cat# 218710,  Trypsin + EDTA Gibco Invitrogen Cat # 25200. 
3.2 Antibodies 
 AKT Phospho (p-129) rabbit monoclonal antibody (1:1000) Epitomics 
(Cat# 5508-1), Akt-1 antibody rabbit polyclonal, Cell Signaling (1:1000, Cat# 
 9272), Actin (p-42) goat polyclonal, Santa Cruz (1:1000, Cat# sc-1616), Cleaved 
Caspase-3 Rabbit polyclonal, Cell Signaling (1:1000, Cat# 9661), Caspase-9 
Mouse monoclonal, Cell Signaling (1:1000, Cat# 9508), CHCM1, rabbit 
polyclonal, 1:4000 was kindly provided Dr M Saeed Sheikh From the Department 
of Pharmacology, State University of New York, Upstate Medical University, 
Syracuse, New York, Lamin A/C rabbit polyclonal, Cell Signaling (1:1000, cat# 
2032), NFkB p65 phosphor serine 529 rabbit polyclonal (human specific) Santa 
Cruz (1:200, Cat#  sc101751), NFkB p65(F-6) mouse monoclonal, Santa Cruz 
(1:200, cat# sc-8008), CKII alpha, rabbit polyclonal, Bethyl (1:3000, cat# A300-
197A), CKII alpha' rabbit polyclonal, Bethyl (1:3000, cat# A300-199A),  
cytochrome C, rabbit monoclonal Epitomics (1:10.000, cat# 3895-1), Lamin A/C, 
rabbit polyclonal, cell signaling (1:100, cat# 2032) p21- (Thr 145)-R rabbit 
polyclonal, santa cruz (1:200, cat3 20220-R), PARP (H-250) rabbit polyclonal 
Santa Cruz (1:1000, cat#sc 7150), Bax (human specific) rabbit polyclonal, cell 
signaling, (1:1000, cat# 2774), Bid (human specific) rabbit polyclonal cell 
signaling, (1:1000, cat#2002), cox IV rabbit IgG, cell signaling (1:1000, 
cat#4850) 
For Immunohistochemistry  
CK2 alpha (C-18), goat polyclonal, santa cruz (1:200, cat# 6479), Ki-67, 
mouse monoclonal, santa cruz (1:50, cat# 23900), NFkB p-65 (A), rabbit 
polyconaol, santa cruz (1:50, cat# sc109)  
 
 
 4X Cracking Buffer 
12ml glycerol, from molecular biology, 99% (Sigma, Cat# G5596), 12mL 
20% SDS, 3mL 1M Tris, pH 6.8, 0.12g Bromophenol blue(free acid) ( Fisher, 
cat# BP115), 1.2mL NanoPure water, 1.8g dithiothreitol (DTT). All the 
components were mixed together thoroughly in 50mL tube, except DTT. DTT 
was added at last then mixed minimally to avoid its oxidation. Aliquoted in 1.5ml 
tubes and stored at -20 ˚C. 
10X Tris Buffer saline 
30.2g Tris (hydroxymethyl)-aminomethane, 99.9+% ultra-pure grade 
(Sigma, Cat# 154563), 87.7g sodium chloride, certified A.C.S (Fisher, Cat# 
S271). Solids were dissolved in ~700ml Nano Pure water on stir plate with stir 
bar. pH was adjusted to 7.4 ( with ~20mL 10M HCL), once dissolved and pH 
adjusted final volume was brought up to 1L.  Stored at room temperature. 
Tris Buffer Saline 
 100ml 10X Tris buffer saline, 900mL Nano Pure water, stored at room 
temperature. 
Tris Buffer Saline + 0.1% Tween-20 (TBS-T) 
 100mL 10X Tris buffer saline, 899mL nano Pure water , 1mL Tween-20, 
sigma Ultra (Sigma, Cat# P7949), stored at room temperature. 
5% Milk Solution 
 5g blotting grade blocker non-fat dairy milk (Bio-Rad, Cat# 170-6404), 
100mL TBS-T. stir on stir plate at room temperature ~1Hr to fully dissolve, stored 
at room temperature. 
Western Blot Stripper  
25ml 0.5M Glycine (Sigma, Cat# G8898), 25ml 20% SDS, 450ml 
NanoPure water, stored at room temperature. 
20% sodium Dodecyl sulphate (SDS)  
100g sodium dodecyl sulphate, for electrophorisis, approx. 99% (Sigma, 
Cat# L3771), 350 Nanopure water, solution was heated upto 68˚C with stirring, 
once dissolved final volume was brought up to 500ml, stored at room temperature 
10X Protein Gel Buffer  
30.275g Tris ((hydroxymethyl)-aminomethane, 99.9+% ultra pure grade 
(Sigma, Cat# 154563), 144.125g Glycine for electrophoresis (Sigma, Cat# 
G8898). Solids were dissolved in ~700ml of Nano Pure water on stir plate with 
stir bar. Once dissolved final volume was brought up to 1L and was stored at room 
temperature. 
Running Buffer   
100ml 10X protein gel buffer, 895ml Nano Pure water, 5ml 20% SDS, 
store at room temperature 
Transfer Buffer: 100mL 10X protein gel buffer, 700mL Nano Pure water, 
200mL 100% Methnol, HPLC grade ( Fisher, Cat# A452) 
 RIPA:            
Final concentration 
7.5mL 5M sodium chloride (Fisher, Cat# S271)    
 150nM 
12.5mL 1M Tris-HCL pH 7.5(made with Sigma, Cat#154563)  
 50nm 
25mL 10% Igepal CA-630, f0r Molecular Biology (sigma, Cat# D6750) 
 1% 
1.25g Sodium deoxycholate, min.97% (sigma, Cat# d6750)   
 0.5% 
1.25ml 20% SDS, for electrophoresis, approx, 99% (Sigma, Cat# L3771)  
25mL glycerol for molecular biology, min. 99% (Sigma, Cat# G5596) 
 10% 
177.5ml nano pure water 
RIPA++:  RIPA, Protease inhibitor (PrI) (Sigma, Cat# P8340) at 1:100, 
Phosphatase inhibitor (PhI) (Sigma, Cat# P0044) at 1:100 
METHODS 
3.3 Setting of the Study 
This study was conducted at the Department of Biochemistry and 
Molecular Biology and Centre for Research in Experimental and Applied 
Medicine (CREAM), Army Medical College, National University of Sciences and 
 Technology, Islamabad. Veteran‟s Medical center Minneapolis, Department of 
Lab Medicine and Pathology University of Minnesota, Minneapolis, USA. 
3.4 STUDY DESIGN 
The study involved two components first component of the study was 
carried out at VA Medical Centre research lab, Minneapolis, USA. It was in vitro 
study involving tissue culture techniques using two types of prostate cancer cell 
lines and benign prostatic hyperplasia cell line. 
The second component of the study involved human samples. This study 
was a cross sectional analytical study, in which human prostate and breast cancer 
tissue specimens were compared for the expression analysis of CK2α, NFkB and 
Ki67 as potential bio-markers for the prognosis of prostate and breast cancer. The 
research protocol was approved from the Ethical Committee, Armed Forces 
Institute of Pathology (AFIP), Combined Military Hospital (CMH), Rawalpindi, 
Pakistan. 
3.5 DURATION OF THE STUDY 
 The duration of the study was 4 years. 
3.6 SAMPLE COLLECTION 
Patients who were on list for the transurethral resection of the prostate 
(TURP) surgery by classified surgeon were recruited in the study. All the samples 
were collected from the operation theatre (OT) of Armed Forces Institute of 
Urology (AFIU), CMH, Rawalpindi. Immediately after the TURP procedure fresh 
tissue samples were collected in formalin from the OT of AFIU.  Next day 
 samples were transferred to 10% buffered formalin. Samples were stored in 
buffered formalin till further processing. Study was approved by Ethical 
committee, and written informed consent of subjects was taken.  
Thirty (30) patients were enrolled in the study. Subjects were divided into 
two groups based upon their histopathological reports by classified pathologist. 
Group1 comprised of 30 cancer patients. Group II consisted of 11 patients 
diagnosed with BPH.  
Thirty (30) Breast cancer tissue samples were obtained from repository of 
AFIP. Internal normal tissue was used as control. 
3.6.1 SAMPLING TECHNIQUE 
Non-probability convenience sampling was carried out and the subjects 
were informed about the purpose of the study and their consent was taken on a 
document prior to sampling. 
3.7 Immunohistochemistry: 
Immunohistochemistry was carried out manually at the histopathology 
laboratory of AFIP.  
3.7.1 Gross 
Each specimen was examined physically by naked eye first. Length, width 
and height were measured. This gives the total size of the tumour tissue. Weight 
was measured. Samples were placed in cassettes for further processing.  
 
 3.7.2 Tissue embedding: 
From formalin tissues were removed for further processing and were 
washed with water for 1h. Samples were proceeded through the following steps 
for embedding in paraffin wax.  
 dehydrate for paraffin embedding (water to paraffin): 
 70% ethanol,1h each, 2 changes,  
 80% ethanol, 1h each, 2 changes 
 95% ethanol, 1h, 2 changes 
 100% ethanol, 1h, 3 changes 
 Xylene, 3 changes, 1h each 
 paraffin wax (56-58ºC) 
 tissues were embedded into paraffin blocks 
3.7.3 Sectioning & Fixation:  
Paraffin embedded sections were cut 3-4 micron thick. Wax ribbon was 
placed in water bath (40˚C-45˚C) with the help of brush. Each section was 
transferred to positively charged slides with a histogrip coating over it. Slides 
were placed in oven for 2 hr at 56˚C for fixation (actual: 20-30 min at 100˚C). 
3.7.4 De-waxing & Rehydration 
 After fixing slides were placed in absolute xylene for de-waxing for 7-10 
min. For rehydration slides were proceeded through ascending grades of alcohol, 
placed first in absolute alcohol for 2-3 min, then in 80% and 70% alcohol for 2-3 
min each. Finally slides were dipped in water to complete rehydration.  
 
 3.7.5 Antigen retrieval 
 For antigen retrieval slides were placed in 10X EDTA + TRIS antigen 
retrieval solution at 100˚C for 25 min in an electric decloaking chamber. After 25 
min slides were placed under running tap water and then were washed with 
distilled water. 
3.7.6 Staining 
 Slides were removed from distilled water. Specimen on each slide was 
encircled with mini pap pen and was immediately placed in PBS to maintain pH 
and to avoid drying of tissue. Hydrogen peroxidase solution (blocking solution) 
was added to each slide. After 5 min slides were washed with PBS three times, 5 
min each. Slides were incubated with primary antibody for 1hr. Slides were 
washed with PBS 3 times, 5min each. Secondary antibody was added for 15 min, 
followed by three washes of PBS 5min each. Streptavidin-HRP was added for 
15mins. Then slides were washed again with PBS. Chromogen DAB was added 
for 10 min. following chromogen staining, slides were washed with distilled 
water. Thereafter, slides were counter stain with haematoxylin for 1min. at the 
end; slides were washed with distilled water 
3.7.7 Dehydration 
 Once staining was completed slides were dehydrated in descending grades 
of alcohol and xylene (90%, 80% and 70%). After staining and rehydration slides 
were mounted with cover slips coated with DPX (Distrene, Plasticiser, Xylene).  
 
 3.7.8 Immuno-Scoring 
Each slide was scored blindly by three histopathologists. In case of 
discrepancy about the result of any sample, two nearest readings were considered. 
For CK2 range of score is from 0-3+ for nuclear and cytoplasmic stain whereas 
extent of staining ranges between 0-4. Sum of these three reading is the total score 
for CK2. For NFkB scoring range is 0-4+ for all the three parameters and sum 
represents the total NFkB value. Ki67 was scored by counting 30 nuclei at five 
different randomly picked representative sections within the same tissue 
specimen. Out of these 30, nuclei stained positively were counted in each section.  
Thus over all totals of 150 nuclei were counted per specimen. Percentage of 
positive nuclei was calculated for analysis, 
3.8 Cell Culture 
3.8.1 Thawing of cells 
Cells were stored in liquid nitrogen. One vial of cell was thawed at a time 
at 37  C for 3 mins in a water bath. Then gently cells suspension was transferred to 
15 ml conical tube containing 5 ml of complete media. Cells were mixed gently 
with media by swirling tube up and down for several times. The tube was 
centrifuged at 200 G for 5 min. Supernantent was discarded and pellet was 
dissolved in 1ml of media. This 1ml was transferred to T-75 flask already 
containing 9 ml of media. Cells were resuspended well by gentle horizontal 
swirling of flask. Cells were allowed to grow till 90% confluent and media was 
changed every fourth day if and when required. 
 
 3.8.2 Cell Lines 
PC3-LN4: Highly metastatic, androgen sensitive prostate cancer cell lines were 
obtained from athymic nude mice by orthotopic implantation within the prostate 
gland (Pettaway et al., 1996). 
B.P.H-1: The immortalized BPH-1 cells were obtained from Dr. Simon Hayward 
(Vanderbilt University, Nashville, TN). 
LNCaP: The LNCaP cells were purchased from ATCC LNCaP clone FGC 
(ATCC® CRL-1740™). 
3.8.2.1 Maintenance of cells     
Androgen sensitive cell line PC3-LN4 was maintained in RPMI 1640 
media with 5% fetal bovine serum (FBS) and 1X penicillin streptomycin (P/S).  
LNCaP and BPH-1 cells were maintained in RPMI 1640 with 10% FBS and 1% 
P/S. 
Cell fractionation 
Cell pellets were suspended gently in 9 packed cell volumes of 
homogenization buffer A1 (10 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 25 mM KCl, 
0.25 M sucrose) with phosphatase and protease inhibitors added at 1:200 just 
before use (Sigma Aldrich: P5726, P8340). The suspension was incubated for 10 
min. on ice to promote cell swelling after which the cells were ruptured using a 
Dounce homogenizer using 9 strokes with an “A” pestle. The suspension was 
centrifuged at 12,000 × g for 30 min at 4 °C to remove the mitochondria. The 
supernatant (cytosolic fraction) was subjected to a second centrifugation at 12,000 
× g for 30 min at 4 °C. The final supernatant was filtered through a 0.2 μm 
 Ultrafree MC filter (Millipore) by centrifuging at 12,000 × g for 2 min at 4 °C. 
Aliquots were flash frozen in liquid nitrogen. 
3.9 Western Blot 
Gel electrophorisis of 50μg of whole cell lysates were carried out for all 
the samples including controls. For time course experiment (cells were treated 
with 80μM TBB for 6Hrs, 24Hrs and 48Hrs) detection of AKT-1, AkT-phospho 
theronine 529, and Lamin A/C was carried out using 10% SDS-polyacrylamide 
gel electrophorsis and 10X protein gel buffer system. For the detection of caspases 
from the same experiment 12% SDS-polyacrylamide gel was used.  
Cytosolic fractions (50 μg ) were run on 15% SDS-polyacrylamide gel 
using 10X protein gel buffer. From both experiments (whole cell lysates and 
cytosolic fraction) proteins were blotted on nitrocellulose membrane. Non-fat 
dairy milk (5%) in 0.1% tween 20 was used for blocking. 0.1% tween 20 was used 
for washing and primary antibody was incubated over night at 4˚C. Next day 
membrane was incubated with secondary antibody for at least hour.  
For western blot analysis cells were plated in 10 cm plate over night so 
that they are 60-70% confluent next day and treated next day according to the 
protocol. Media from each plate was collected in 15 ml conical tube; cells were 
trypsinized with 1.5ml of trypsin till all the cells were floating and dislodged. 
Media (5ml) was added and cells were resuspended in this media. This cell 
suspension was also added to the respective conical tube. All the tubes were 
centrifuged at 1000 RMP for 5 min. Supernatant was discarded and pellet was 
dissolved in 3-5 ml of phosphate buffer saline (PBS). Again tubes were 
 centrifuged at 1000 RMP for 5 min. Supernatant was discarded; pellet was 
dissolved in 1ml of PBS and transferred to 1.5 ml eppendrof tubes. Tubes were 
centrifuged at 5000 RMP for 5mins. Supernatant was discarded and pellets were 
stored at -80˚C till further used.  
Protein (50μg) from sample was aliquoted into 1.5 ml microfuge tubes. 
Samples were flash frozen in liquid nitrogen then placed at -80˚C for long term 
storage. 
3.9.1 Sample Preparation Protocol 
Aliquots of 50μg were thawed on ice when ready to process. All the 
samples were brought upto the same volume using ½ x RIPA. Appropriate volume 
of 4 x cracking buffer was added so as the final concentration was 1 x in solution. 
Vortex samples for 5 sec. The tubes were placed in a heat block at 95˚C for 10 
min. After 10 min samples were allowed to thaw at room temperature for 1min in 
a tube rack. Tubes were spin at high speed (13,200 RPM) for 15 sec. Marker tube 
was spin for 7 sec. at 1000 RPM.  Protein ladder (10uL) and samples were loaded 
onto the gel. 
3.9.2 Bradford Protein Concentration Assay 
Beginning with the frozen cell pellets in 1.5 ml tubes on ice, appropriate 
(i.e. pcv=20μl, ~150μL RIPA++) amount of ice cold RIPA++ buffer with protease 
and phosphatise inhibitor (1:100 each) was added. Pellet was resuspended in this 
solution until homogeneous mixture was formed. Tubes were vortexed for 3 
seconds each, and then were spine in 4 ˚C centrifuge for 5mins at 14,000 RPM. 
Supernatant was transferred into ice chilled relabelled tubes using a pipette and 
 leaving pellet intact in the original tube. Supernatant of 5μL this protein was 
diluted in 95μL of Nano-pure water. Each tube was vortex for 3sec. BSA (Bovine 
Serum Albumin) stock and standards were prepared as follows. 
Diluted RIPA stock = 50μl of RIPA buffer + 950μL NanoPure water 
Diluted BSA stock = 25μL of BSA + 175μL diluted RIPA stock (Pierce 
stock = 2μg/μL (1:8 for final concentration of 0.25 μg/μl) 
Standards Diluted RIPA Stock volume (μL) Diluted BSA stock Volume (μL) 
Blank 50 0 
0.0μg 50 0 
0.25μg 45 5 
0.5μg 40 10 
1.0μg 30 20 
2.0μg 10 40 
2.5μg 0 50 
 
BSA (10uL) standards and diluted protein supernatant were pipette in 
appropriate well in 96-well plate; all the samples and standards were pipette in 
triplicate. 200μL of coomassie protein Assay reagent was added to each well. 
Plate was mixed on mocroplate genie for 10 sec. Absorbance was read at 595 nm 
using a plate reader.  
The R
2 value from standard curve was ≥ 0.99 and CV% of each standard 
and sample were > 10%. 
 
 3.10 Cell Viability/ CellTiter Aqueous One Assay 
Cells were plated in 96-well plate at concentration of 4000 cells/plate 
overnight. Next day wells were treated according the protocol for the time point 
under investigation. With TBB 2hrs, 4hrs, 6hrs, and 24hrs time point was tested at 
8μm and 80μM concentration. Each experiment contained Dimethyl 
sulfoxide (DMSO) and untreated control as well media only wells for background 
readings. For TBCA cells were plated overnight in 96-well plate at 4000cells/well. 
Next day wells were treated with 1μm, 10μM, 20μM, 40μM, 80μM and 160μM 
TBCA for 24hrs. DMSO (20μM, 80μM and 160μM) and untreated controls were 
included as well as media only for back ground readings. Cell Titer Aqueous one 
solution was combined with media in ratio of 100μl media plus 20μl of assay 
solution per well. Using a multichannel pipette media was removed from wells. 
Aqueous one plus media solution (120μl) was added to each well. Media was 
added in triplicate in separate wells as control. This reading was then subtracted 
from all the readings. Plate was incubated for 3hrs at 37 ˚C. Absorbance was 
measured at 490nm and 700nm (for debris background) using a plate reader  
3.11 Coating of Cover slips with Matrigel: 
Cover slips were washed for sterilization with 70% ethanol twice for 1min, 
then were place in hood with UV on for 1h. Using clean sterilized forceps, single 
cover slip was placed in each well. 500μL of matrigel was dissolved in 14.5ml of 
ice cold DPBS. The solution was filtered by passing through syringe driven filter 
unit PES 0.22μM (Milliex, Millipore, cat# 2014-110). 750μL of this solution was 
 added to each well containing cover slip. Plates were placed over night in hood to 
dry. Next morning plates were sealed with paraffin film till further use. 
3.12 Fluorescence Imaging   
Cell were plated on cover slips coated with matrigel in 6-well plates 
overnight to be approximately 60-70% confluent next day. Each well was treated 
according to respective experiment and protocol for 2hrs, 4hrs, 6hrs and 24hrs 
with either TBB (8μM, 80μM), TBCA (20μM, 80μM). All experiments included 
DMSO control (80μM volume equalling of TBB or TBCA) untreated cells, 
controls CCCP and oligomycin (30 min. treatment, last 30 min. of the time period 
under investigation). JC-1 was added to each well at 5μg/ml concentration for 2hrs 
and cells were incubated at 37˚C and 5% CO2. For 1hr time JC-1 was added for 
1hr. After completion of experiments cover slips were inverted on slides coated 
with slow-fade anti gold solution. Images were taken immediately at 20X and 
40X. Olympus BX60 conventional compound fluorescence microscope was used 
for imaging. For detection of red fluorescence cells were viewed under cy3 filter 
(Excitation= 495nm, emission= 519nm) and for observing green fluorescence 
cells were observed under fluorescein channel (excitation= 512,552nm, 
emission=565,615nm). The data presented in the tables represent counting cells in 
4 fields (60 – 100 cells per field) per condition from 3 different experiments for 
the PC3-LN4/TBB, 2 different experiments for the PC3-LN4/TBCA, 2 different 
experiments for BPH-1/TBB, and 1 experiment for LNCaP/TBB. 
 
 
 3.13 Statistical Analysis 
The primary cell line for study of the various parameters was PC3-LN4, 
and most experiments using these cells were performed at least three times. The 
data are expressed as mean ± SEM. To determine the generality of the results 
obtained for Δψm changes in PC3-LN4 cell line, they were confirmed in two other 
cell lines (LNCaP and BPH-1); in this case the experiments were performed 2 and 
1 times, respectively. Statistical significance was analyzed for the Aqueous One 
cell viability using analysis of variance with Bonferroni correction, and for clonal 
survival using t-tests. 
Chi square test was used to determine association between the pathological 
features and stating pattern of CK2, NFkB and Ki67. Linear Regression analysis 
was carried out to find the relationship between the CK2, NFkB and Ki67 in 
pathogenesis of disease. Independent students t-test was used to compare the 
means of BPH and cancer scoring. 
 
 
 
 
 
 
 Chapter 4 
OBESERVATIONS and RESULTS 
4.1 Cell survival Experiments; Effect of TBB on prostate Cancer 
Cells, PC3-LN4 
Experiments were undertaken to determine the time course of the effect of 
inhibition of CK2 on cell viability in the presence of the relatively specific CK2 
inhibitor TBB at varying concentrations. In these experiments we determined the 
effects of TBB treatment for much shorter time periods than previously examined. 
We employed the CellTiter 96® Aqueous One assay which measures the 
bioreduction (thought to occur via NADPH/NADH) of an MTS tetrazolium 
compound to a colored formazan product whose quantity as measured by 
absorbance at 490 nm is directly proportional to the number of metabolically 
active cells (Berridge and Tan, 1993). This assay is a snapshot of the bioreduction 
activity of the cells at the specific time-point during the incubation. The results in 
Fig. 6A demonstrate that PC3-LN4 cells treated with TBB at 80 μM begin to 
show a change in viability as early as 2 h following the addition of TBB, although 
this change is not statistically significant. There is a successive decrease in the 
viability of cells up to 6 h (Table 1A, Fig. 6A) but this decrease is not statistically 
significant till 24 h. By 24 h and 48 h the respective cell viability was 40% and 
22%, as indicated graphically in (Table 1B, Fig. 6B).  
Similar observations were made when cells were treated with another CK2 
inhibitor TBCA, although a less dramatic loss of viability at 24 and 48 h using 80 
μM TBCA was observed (Fig. 7A). Characterization and comparison with TBB, 
 of TBCA was carried out in PC3-LN4 prostate cancer cells over the 48 h. 
successively increasing concentrations of TBCA were tested, starting from 1μM 
till 160μM. At 24 h only 160μM TBCA significantly decreased the viability of 
PC3-LN4 and was comparable to 80μM TBB (Table 2A, Fig 7A). At 48 hrs 80μM 
and 160μM TBCA significantly decreased the viability of PC3-LN4 cells (Table 
2B, Fig. 7B).  
4.2 Crystal Violet Clonal Survival Assays 
In order to assess the survival and proliferative capacity of the cells over a 
period of 7 days following TBB treatment, crystal violet clonal survival assays 
were carried out following 4, 6, 8, and 24 hrs treatment with TBB. In this assay, 
TBB was removed from the cells after the indicated period of treatment, and the 
cells were replated in complete media. At 4 hrs there was no significant difference 
between the un-treated and 80μM TBB treated cells. The results demonstrated that 
6 hrs of treatment with 80 μM TBB was sufficient to cause significant loss of cell 
proliferation and survival. This loss was further augmented with the passage of 
time till 24 hrs (Fig. 8A & B). 
 
 
 
 
 
 
 Table 1A:  Aqueous One assay, 2 hrs, 4 hrs & 6 hrs TBB treatment of PC3-
LN4. All values are represented as mean ±SEM (related to un-treated). Mean is 
representative of three independent experiments. Un-treated (Unt) and DMSO 
treated cells served as control. 
 
Unt 
6 hrs 
DMSO 
6 hrs 
80 
TBB 
6 hrs 
8 
TBB 
4 hrs 
DMSO 
4 hrs 
80 
TBB 
4 hrs 
8TBB 
2 hrs 
DMSO 
2 hrs 
80 
TBB 
2 hrs 
8TBB DCA 
            
Rel to 
Unt 1 0.79 0.72 0.96 0.98 0.74 0.89 0.82 0.82 0.90 0.78 
Rel to 
Unt 1 1.02 0.83 1.27 1.00 0.85 1.19 0.87 0.92 1.21 0.92 
Rel to 
Unt 1 1.03 0.61 1.08 0.95 0.81 1.07 1.17 0.84 0.89 0.93 
MEAN 1 0.94 0.72 1.10 0.98 0.79 1.05 0.95 0.86 1.00 0.88 
STDEV 0 0.10 0.09 0.13 0.02 0.05 0.12 0.15 0.05 0.15 0.06 
SEM 0 0.06 0.05 0.07 0.01 0.03 0.07 0.09 0.02 0.08 0.04 
 
Rel to Unt: relative to untreated; STDEV: Standard deviation; SEM: standard 
Error Mean 
 
 
 
 
 
 
  
 
 
Figure 6A: Time course changes in mean (±SEM) cell viability of PC3-LN4 cells 
after treatment with 8μM and 80μM TBB treatment. Mean represents three 
independent experiments.  
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 Table 1B: Aqueous One Cell Viability Assay: 24Hrs 80μM TBB treatment of 
PC3-LN4. All values are represented as mean ±SEM (related to un-treated). Mean 
is representative of three independent experiments. * shows a statistically 
significant result (P<0.05) 
 
Un-treated 
(Unt) DMSO 80TBB 
Rel TO Unt 1 1.00 0.54 
Rel to Unt 1 1.01 0.64 
Rel to Unt 1 0.96 0.43 
MEAN 1 0.99 *0.54 
STDEV 0 0.029 0.11 
SEM 0 0.02 0.06 
Rel to Unt: relative to untreated; STDEV: Standard deviation ; SEM: standard 
Error Mean 
 
Figure 6B: Effect on cell viability over 24 hrs after 80μM TBB treatment of 
PC3-LN4 cells. All values are represented as mean ± SEM. Mean represents three 
independent experiments. ANOVA (Bonferroni correction) * P<0.05  
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 Table 2A: 24 hrs cell viability aqueous one assay. Characterization and 
comparison of TBCA treatment with TBB treatment on PC3-LN4 cell line. All 
values are represented as mean ± SEM. Mean represents three independent 
experiments 
 
Rel to Unt: relative to untreated; STDEV: Standard deviation; SEM: standard 
Error Mean 
 
 
 
 
 
 
  
Un-
treated 
 
1μM 
TBCA 
 
10μM 
TBCA 
 
20μM 
TBCA 
 
40μM 
TBCA 
 
80μM 
TBCA 
 
160μM 
TBCA 
 
80μM 
TBB 
 
20μM 
DMSO 
 
80μM 
DMSO 
 
            
Rel to 
Unt 1 0.776 0.919 0.599 0.704 0.762 0.351 0.391 0.807 1.009  
Rel to 
Unt 1 1.122 0.995 1.050 0.986 0.823 0.471 0.428 0.856 0.961  
Rel to 
Unt 1 1.066 1.093 1.118 1.136 0.825 0.429 0.407 0.948 1.089  
 
MEAN 1 0.988 1.002 0.922 0.942 0.803 0.417 0.409 0.870 1.019  
 
STDEV 0 0.185 0.087 0.282 0.219 0.036 0.060 0.018 0.071 0.064  
 
SEM 0 0.107 0.050 0.163 0.126 0.020 0.0351 0.010 0.041 0.037  
  
 
 
Figure 7A: Effect of increasing concentrations of TBCA on PC3-LN4 over 
24 hrs. All values are represented as mean ± SEM. Mean represent three 
independent repeats. ANOVA (Bonferroni correction) * p< 0.05  
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 Table 2B: 48Hrs cell viability aqueous one assay. Characterization and 
comparison of TBCA treatment with TBB treatment on PC3-LN4 cell line. All 
values are represented as mean ± SEM. Mean represents three independent 
experiments. 
 
Rel to Unt: relative to untreated; STDEV: Standard deviation; SEM: standard 
Error Mean 
 
 
 
 
 
 
 
  
Unt 
 
1uM 
TBCA 
 
10uM 
TBCA 
 
20uM 
TBCA 
 
40uM 
TBCA 
 
80uM 
TBCA 
 
160uM 
TBCA 
 
80uM 
TBB 
 
20uM 
DMSO 
 
80uM 
DMSO 
           
Rel to 
Unt 1 0.982 0.980 1.004 0.812 0.516 0.185 0.234 0.991 1.072 
Rel to 
Unt 1 0.726 0.847 0.671 0.793 0.448 0.093 0.168 0.736 0.712 
Rel to 
Unt 1 0.962 1.105 1.173 0.991 0.632 0.161 0.264 1.082 1.070 
 
MEAN 1 0.890 0.977 0.950 0.865 0.532 0.146 0.222 0.936 0.951 
 
STDEV 0 0.142 0.129 0.255 0.109 0.092 0.047 0.049 0.179 0.207 
 
SEM 0 0.082 0.074 0.147 0.063 0.053 0.027 0.028 0.103 0.119 
  
 
 
 
Figure 7B: Effect of increasing concentrations of TBCA on PC3-LN4 over 
48Hrs. All values are represented as mean ± SEM. Mean represent three 
independent repeats. ANOVA (Bonferroni correction) *p< 0.05  
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Figure 8A: Clonal survival in cells treated with 80μM TBB, inhibitor of CK2. 
PC3-LN4 cells were treated for a varying periods of  time (4-24 hrs). Values 
are represented as related to % change to DMSO ± SEM. Mean values are 
representative of three independent experiments. *p≤ 0.05 and #p≤0.0001. 
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Figure 8b: clonal survival of cells treated with 80 μM of TBB for varying 
periods of time (4 to 24 h). Representative colony formation and statistical 
analysis showed that cells started to lose their ability to revive at 6 hrs onwards.  
 
 
 
 
 4.3 Inhibition of CK2 by TBB; effect on mitochondrial 
membrane potential 
 PC3-LN4 cells were treated with 8uM and 80uM TBB for 2, 4, 6 and 24 
hrs. JC-1 uptake by these cells under microscope showed rapid loss of 
mitochondrial membrane potential (Δψm) as early as at 2 h after the treatment 
with 80uM TBB. This loss was in a dose dependent manner as 8uM TBB has a 
lesser effect at all the time points. Red JC-1 fluorescence capture indicates intact 
Δψm, whereas green JC-1 fluorescence capture indicates that membrane potential 
has been lost. Intermediate stage between the two stages was also observed 
indicated by appearance of yellow color. Changes in membrane potential occurred 
in the time dependent manner which started to appear at 2h and there was a 
complete loss of mitochondrial membrane potential at 24 h, table 3A, and figure 
9A. DMSO and un-treated cells served as control. At all time points controls had 
intact mitochondrial membrane potential 
Similar experiments were carried out in LNCaP and B.P.H-1 cell lines. 
LNCaP showed similar results as those observed in PC3-LN4. Cells were treated 
with 80uM TBB at 4, 6 and 24 hrs. Treatment with 80uM TBB resulted in loss of 
Δψm at 4hrs. This loss in Δψm occured in dose and time dependent manner, table 
3B and figure 9B. 
The Δψm change in the benign prostate epithelial cell line (BPH-1) was 
notably lower in response to TBB under similar conditions (Fig. 9C). The 
quantitation of these data is presented in Table 3C. 27% of cell showed loss in 
mitochondrial membrane potential at 2 h. which increased up to 42% of cells at 4 
 h. At 6h 69% of cells lost their Δψm. At 24 h almost 50% of the B.P.H-1 cells lost 
their Δψm. 
Another CK2 inhibitor TBCA was also employed to carry out the same 
series of experiments on PC3-LN4 cell lines. The effects of TBCA-mediated CK2 
inhibition were slightly less dramatic but essentially the same as TBB. More than 
50% of the cells lost their Δψm at 2 h (yellow+ green color indicates the loss of 
Δψm) when treated with 80 uM TBCA. Loss in The loss in Δψm occurred in dose 
and time dependent manner table 4 and figure 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3A: Effect of TBB on mitochondrial membrane potential in PC3-LN4 
cells over time 
a The mitochondrial membrane potential Δψm is represented by red (high), 
yellow (low), and green (none). Data are presented as mean ±SEM. The amount of 
DMSO as the control corresponded to that in the higher concentration of TBB. 
b These cells demonstrated red fluorescence that was not similar in intensity to 
that in the control cells but had a greenish hue suggesting that the estimate of the 
cells showing high Ψm might be apparently too high in this case. 
Time of 
treatment 
(hr) 
Agent Mitochondrial membrane potential (Ψm) 
in PC3-LN4 cells
a
 
 
 
2 
High Ψm 
(red) 
Low Ψm 
(yellow) 
No Ψm 
(green) 
None 80.7 ± 6.9 18.9 ± 2.3 0 
DMSO 64.2 ± 4.2 35.4 ± 6.1 0 
8 µM TBB 55.1 ± 5.9 39.8 ± 3.6 11.8 ± 1.2 
80 µM TBB 16.8 ± 1.3 0.6 ± 0 82.7 ± 2.2 
4 None 93.4 ± 3.5 5.1 ± 3.4 1.3 ±0 
DMSO 93.9 ± 4.8 6.7 ± 2.7 0 
8 µM TBB 66.1 ± 4.6 29.1 ± 4.0 3.7 ± 1.4 
80 µM TBB 0.3 ±  0 0.1 ±  0 99.4 ± 8.2 
6 None 90.5 ± 4.5 9.2 ±4.5 0.3 ± 0 
DMSO 85.5 ± 4.6 14.5 ± 4.6 0 ± 0 
8 µM TBB 41.0 ± 4.7 41.2 ± 4.1 17.8 ± 2.6 
80 µM TBB 0.9 ± 0 0 ± 0 99.1 ± 1.5 
24 None 97.0 ± 0.2 2.2 ± 0 0 ± 0 
DMSO 98.9 ± 0.4 0.5 ± 0 0 ± 0 
8 µM TBB 58.2 ± 3.1
b
 13.7 ± 2.5 28.1 ± 2.2 
80 µM TBB 0.7 ± 0 0 ± 0 99.2 ± 1.9 
 
  
Figure 9A: Changes in mitochondrial membrane potential (Δψm) caused 
by treatment of cells with the CK2 inhibitor TBB.  PC3-LN4 cells were treated 
with 8 or 80 μM TBB as shown. DMSO control cells were treated with a volume 
of DMSO equivalent to that for 80 μM TBB. The period of treatment varied from 
2 to 24 h. Red color indicated intact (Δψm). Loss of red and acquisition of green 
color indicates loss of (Δψm). Images where taken at 40 x. 
 
 
 
 
 Table 3B:  Effect of TBB on mitochondrial membrane potential in LNCaP 
cells over time 
a The mitochondrial membrane potential Δψm is represented by red (high), 
yellow (low), and green (none). Data are presented as mean ±SEM. The amount of 
DMSO as the control corresponded to that in the higher concentration of TBB. 
 
 
Time of 
treatment 
(hr) 
 
 
Agent 
 
Mitochondrial membrane potential (Ψm) 
in LN-CaP cells
a
 
 
 
 
 
High Ψm 
(red) 
 
Low Ψm 
(yellow) 
 
No Ψm 
(green) 
4 None 81.±2.5 18.5±1.5 0 
8 µM TBB 45.7±1.5 10.0±3.5 44.2±1.8 
80 µM TBB 15.6±3.3 0 84.4±5.6 
6 None 90.9±1 9.1±1.2 0 
8 µM TBB 55.0±1.8 9.4±0.6 35.6±2.2 
80 µM TBB 19.9±1.5 0 80.1±6 
24 None 87.1±1.3 12.9±0.8 0 
DMSO 93.6±2.3 6.4±1.2 0 
8 µM TBB 43.9±5.9 16.1±1.8 40±1.7 
80 µM TBB 23.2±1.9 2.8±0.9 74.0±3.3 
 
 
  
Figure 9B: Changes in mitochondrial membrane potential (Δψm) caused 
by treatment of cells with the CK2 inhibitor TBB.  LNCaP cells were treated 
with 8 or 80 μM TBB as shown. DMSO control cells were treated with a volume 
of DMSO equivalent to that for 80 μM TBB. The period of treatment varied from 
4 to 24 h. Red color indicated intact (Δψm). Loss of red and acquisition of green 
color indicates loss of (Δψm). Images where taken at 40 x. 
 
 
 Table 3C:   Effect of TBB on mitochondrial membrane potential in BPH-1 
cells over time 
a The mitochondrial membrane potential Δψm is represented by red (high), 
yellow (low), and green (none). Data are presented as mean ±SEM. The amount of 
DMSO as the control corresponded to that in the higher concentration of TBB. 
Time of treatment 
(hr) 
 
 
Agent 
 
Mitochondrial membrane potential (Ψm) 
in B.P.H-1 cells
a
 
 
 
2 
High Ψm 
(red) 
Low Ψm 
(yellow) 
No Ψm 
(green) 
None 73.7 ± 5.6 12.5 ± 3.1 0 
DMSO 85.1 ± 4.5 14.8 ± 4.2 0.12 ± 0 
8 µM TBB 81.25 ± 
3.6 
14.9 ± 
2.00 
3.84 ± 2.0 
80 µM 
TBB 
71.7 ± 6.3 13.8 ± 2.8 13.6 ± 2.6 
4 None 89.7 ± 6.6 4.4 ±1.31 5.9 ± 20.5 
DMSO 94 ± 3.33 3.9 ± 0.9 4.5 ± 0.5 
8 µM TBB 54.1 ± 1.8 13.6 ± 2.0 35.4 ± 9.1 
80 µM 
TBB 
13.4 ±9.62  16 ± 2.7 25.8 ± 2.2 
6 None 88.6 ± 7.9 11.4 ±  1.9 0 
DMSO 85.1 ± 3.9 13.9 ± 1.4 0 
8 µM TBB 63 ± 3.7   21.5 ± 2.8 15.4 ± 1.1 
80 µM 
TBB 
30.3 ±6  20.7 ± 1.3 48.4 ± 1.8 
24 None 95.5±2 4±2.1 0 
DMSO 91.7±12.6 8.4±1.5 0 
8 µM TBB 66.9±1.8 20.3±1.6 11.4±1.4 
80 µM 
TBB 
52.5±7.1 15.8±2.5 31.6±2 
 
  
Figure 9C: Changes in mitochondrial membrane potential (Δψm) caused 
by treatment of cells with the CK2 inhibitor TBB.  B.P.H-1 cells were treated 
with 8 or 80 μM TBB as shown. DMSO control cells were treated with a volume 
of DMSO equivalent to that for 80 μM TBB. The period of treatment varied from 
2 to 24 h. Red color indicated intact (Δψm). Loss of red and acquisition of green 
color indicates loss of (Δψm). Images where taken at 40 x. 
 
 
 
 
 Table 4:  Effect of TBCA on mitochondrial membrane potential in PC3-LN4 
cells over time 
a The mitochondrial membrane potential Δψm is represented by red (high), 
yellow (low), and green (none). Data are presented as mean ±SEM. The amount of 
DMSO as the control corresponded to that in the higher concentration of TBCA. 
 
 
 
 
  
Figure 10: Changes in mitochondrial membrane potential (Δψm) caused 
by treatment of cells with the CK2 inhibitor TBCA.  PC3-LN4 cells were 
treated with 20 or 80 μM TBCA as shown. DMSO control cells were treated with 
a volume of DMSO equivalent to that for 80 μM TBB. The period of treatment 
varied from 2 to 24 h. Red color indicated intact (Δψm). Loss of red and 
acquisition of green color indicates loss of (Δψm). Images where taken at 40 x. 
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 4.4 Effect of catalase on CK2 inhibition mediated change in 
mitochondrial membrane potential 
To test whether the production of hydrogen per oxide (H2O2) is the prior 
event or loss of mitochondrial membrane potential occurs at an even earlier time, 
PC3-LN4 cells were treated with reactive oxygen species (ROS) scavenger 
catalase. 3000 and 6000 units of catalase were added to PC3-LN4 for 1 h prior to 
inhibition of CK2 with 80 μM TBB for 4 h. The results indicated that there was no 
effect of catalase treatment on Δψm under these conditions, suggesting that the 
Δψm change in prostate cancer cells occurred prior to the production of H2O2 
(Fig. 11, left panels). 
4.5 Effect of BAPTA on CK2 inhibition mediated change in 
mitochondrial membrane potential 
To determine the role of calcium (Ca2+) signaling in initiation of loss 
Δψm PC3-LN4 cells were treated with the Ca2+ chelator BAPTA (10 μM) for 1 h 
prior to treatment of cells with 80 μM TBB for 4 h. As shown in Fig. 11, center 
panels, pre-treatment of cells with BAPTA prevented Δψm loss suggesting a role 
of Ca2+ in promoting these changes in response to CK2 inhibition. These results 
predict the involvement of Ca2+ signaling as an early response to inhibition of 
CK2 activity in promoting loss of Δψm. 
 
  
Figure 11 Mitochondrial membrane potential change mediated by CK2 
inhibition is blocked by pretreatment of cells with BAPTA but not catalase. 
PC3-LN4 cells were treated with catalase (3000 units) or BAPTA (10 μM) for 1 h 
followed by treatment with 80 μM TBB for 4 h. JC-1 loading was performed for 
the final 1 h of incubation. Controls included pretreatment for 1 h with drug 
solvent (DMSO for BAPTA; 50 mM potassium phosphate buffer pH 7.0 for 
catalase) followed by DMSO. Untreated cells were analyzed as a further control. 
Panels are accordingly labeled. Mitochondrial membrane potential was measured 
as described under Experimental Procedures. 
 4.6 Temporal relation of CK2 inhibition and mitochondrial 
membrane potential changes compared with other markers of 
apoptosis 
To further identify the direct effect of CK2 inhibition on mitochondrial 
integrity and temporal response of various mitochondrial apoptotic signals, we 
examined CHCM1, inner mitochondrial membrane protein and several markers of 
apoptosis over time following treatment of cells with TBB. The results in Fig. 12 
show the effect of treating PC3-LN4 cells with 80 μM TBB for varying periods of 
time. In cytosolic lysates in which the mitochondria have been removed by 
centrifugation, loss of full length Bid compared to DMSO controls was apparent 
from 4 h through 24 h. In the same cytosolic lysates, release of cytochrome c and 
Cox IV from the mitochondria into the cytosol was evident at 24 h (Fig. 12). 
Analysis of other signals associated with apoptosis such as lamin A/C, caspase-9, 
and caspase-3 cleavage was performed in whole cell lysates and indicated their 
appearance at 24 h (Fig. 12B & 13A). The effectiveness of TBB as inhibitor of 
CK2 was also analyzed by examining the phosphorylation status of AKT-1. The 
inhibition of phosphorylation at Ser129 which is a specific target of CK2 was 
indicated at 24 h and further increased at 48 h following treatment with TBB (Fig 
13B). Concurrent loss of the general AKT-1 signal was also observed and was 
specific to TBB and not etoposide treatment (Fig 13A & B). Down regulation of 
CHCM1 showed that mitochondrial inner membrane structural integrity is also 
compromised by CK2 inhibition   (Fig. 13A and 13B). 
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FIGURE 12: Temporal response of CK2 substrate and apoptotic signals 
following TBB mediated inhibition of CK2 in PC3-LN4 cells. A. Effect of 80 
μM TBB treatment of cells for varying times on apoptotic signals measured in the 
cytosol. Cells were treated with TBB for 4, 6, 8 and 24 h. Analysis of Bid, 
cytochrome c, and Cox IV was carried out in the purified mitochondria-free 
cytosolic fractions. B. Effect of 80 μM TBB treatment of cells for varying times in 
whole cell lysates. Cells were treated with TBB for 6, 24, and 48 h as shown, with 
DMSO as the corresponding control. Full length and cleaved caspase 9, cleaved 
caspase 3 were analyzed. Etoposide (100 μM for 24 h) was employed as the 
positive control for induction of apoptosis. 
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FIGURE 13: Temporal response of CK2 substrate and apoptotic signals 
following TBB mediated inhibition of CK2 in PC3-LN4 cells. A. Effect of 
80 μM TBB treatment of cells for varying times in whole cell lysates. Cells 
were treated with TBB for 6, 24, and 48 h as shown, with DMSO as the 
corresponding control. Full length and cleaved lamin A/C, total and phospho-
Ser129 AKT-1 were analyzed. Etoposide (100 μM for 24 h) was employed as 
the positive control for induction of apoptosis. All other details were as 
described under Experimental Procedures. B. Graphic representation of down 
regulation of Akt, Akt-phospho and CHCM1over period of time after treatment 
of cells with 80 uM TBB 
0
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 4.7 Clinical and Pathological Characters of Patients with 
Adenocarcinoma of Prostate 
Table 5 represents the observations obtained from the data base of patients 
at department of histopathology at the AFIP. All the clinical and pathological 
grades were assigned by the classified histopathologist. Values are represented as 
mean. Total 30 patients were enrolled in the study with mean age of 69.6 years. 
Mean Gleason Score is 7.13. 30% of patients had lymphovascular invasion 
whereas pernural invasion was observed in 43.3% of patients. 60.3% of patients 
had ≥ 70% of prostatic tissue involved. 
4.8 Immunohistochemical Expression pattern of CK2, NFkB and 
Ki67 in prostatic Cancer tissue 
Figure 14A represents the normal internal control of prostate cancer tissue. 
Normal surrounding cells did not take up stain for any of the marker studied. 
Hematoxylin and eosin (H&E) staining was carried on every sample to determine 
the pathological stage of the tumor, figure 14B is the representative H&E figure. 
To determine the expression pattern (cytoplasmic, nuclear and extent of staining) 
of CK2, NFkB and Ki67 immunohistochemistry was carried out. Staining was 
scored. For CK2 range of score is from 0-3+ for nuclear and cytoplasmic stain 
whereas extent of staining ranges between 0-4. Sum of these three reading is the 
total score for CK2, figure 15(A, B and C). For NFkB scoring range is 0-4+ for all 
the three parameters and sum represents the total NFkB value, figure 16(A, B & 
C). Ki67 was scored by counting 30 nuclei at five different randomly picked 
representative sections within the same tissue specimen. Out of these 30, nuclei 
 stained positively were counted in each section.  Thus over all totals of 150 nuclei 
were counted per specimen. Percentage of positive nuclei was calculated for 
analysis, figure 17 (A, B & C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 5: Clinicopathological features of patients with adenocarcinoma of 
prostate. Values are represented as mean for age and Gleason score. Actual 
values are given for perinural/lymphovascular invasion and percentage of tissue 
involved. Frequency of each feature is represented as percentage.  
 
Cliniopathological features                              Scores 
Mean Age                                                    69.6 years (28-90) 
Mean Gleason Score                                                 7.13 (5-9) 
≤ 6                                                                                         8 
≥ 7                                                                                       22 
Lymphovascular Invasion present                                9 (30%) 
Lymphovascular Invasion Absent                              21 (70%) 
Perinural Invasion Present                                          13 (43.3%) 
Perinural Invasion Absent                                          17 (56.7%) 
Percentage of Prostatic Tissue Involved 
≤ 60%                                                                          11(36.7%) 
≥ 70%                                                                          19 (63.3%) 
 
 
 
 
 
 
 
 
 
 
 
 
                                         
 
 
Figure 14: Representative H&E staining of tumor tissue, to determine the 
histological parameters of the disease. 
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Figure 15: Immunohistochemical Expression pattern of CK2. Prostate 
adenocarcinoma tissue samples were stained using the DAB method to determine 
the expression pattern of CK2. Acquisition of brown color shows the positive 
staining. CK2 was scored in both nuclear and cytoplasmic compartment. Scoring 
range is 0-3+ and extent of staining was also scored (0-3+). Figure A shows no 
nuclear staining with 1+ cytoplasmic stain and 1+ extent of staining. Figure B 
shows the positive staining with scores as nuclei 1+, cytoplasmic 2+ and extent 2+ 
this makes the total CK2 score of 5+. Figure C scoring is nuclei 2+, cytoplasmic 
3+ and extent 2+. Figure D is nuclei 3+, cytoplasmic 3+ and extent 3+, total CK2 
score is 9+.      Indicates nuclear staining  
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Figure 16: Immunohistochemical Expression pattern of NFkB. Prostate 
adenocarcinoma tissue samples were stained using the DAB method to determine 
the expression pattern of NFkB. Acquisition of brown color shows the positive 
staining. NFkB was scored in both nuclear and cytoplasmic compartment. Scoring 
range is 0-4+ and extent of staining was also scored (0-3+). Figure A shows no or 
0 nuclear staining with 1+ cytoplasmic stain and 1+ extent of staining. Figure B 
shows the positive staining with scores as nuclei 1+, cytoplasmic 2+ and extent 2+ 
this makes the total NFkB score of 5+. Figure C scoring is nuclei 2+, cytoplasmic 
1+ and extent 2+. Figure D is nuclei 3+, cytoplasmic 2+ and extent 2+, total NFkB 
score is 8+. Figure E shows nuclear staining score as 4+, cytoplasmic score 4+ 
and extent as 3+. Nuclear is staining indicated by   
 
 
 
 A 
 
B 
 
 
 
 
 
 
  
 
C 
 
Figure 17: Immunohistochemical Expression pattern of Ki67. Prostate 
adenocarcinoma tissue samples were stained using the DAB method to determine 
the expression pattern of Ki67. Acquisition of brown color shows the positive 
staining. Ki67 was scored by counting 30 nuclei at five different randomly picked 
representative sections within the same tissue specimen. Out of these 30, nuclei 
stained positively were counted in each section.  Thus over all totals of 150 nuclei 
were counted per specimen. Percentage of positive nuclei was calculated for 
analysis.  A result of less than 10% is considered low, 10-20% borderline, and 
high if more than 20%. A. shows the ki67 score of 4%. B. cells with 16% positive 
Ki67 nuclei. C. shows the 33% staining for Ki67.       Indicates  nuclear positive 
staining. 
 4.9 Evaluation of CK2α as potential prognostic marker; Co-
relation of CK2, NFkB and Ki67 with clinicopathological features 
and stage of cancer:  
Immunohistochemical analysis was carried to measure expression of 
CK2α, NFkB and ki67. Then we determined the relationship of CK2α, NFkB and 
Ki67 expression with risk factor (age) as well as pathological stage of the disease 
(gleason score, lymphovascular and perinural invasion and percentage of prostatic 
tissue involved). Table 6A shows the descriptive statistics for all the variables. 
CK2 and NFkB were over expressed in all the tissues examined.  
4.9.1 Age 
No significant association was found between the total CK2 score and age 
of patients (p=0.1). When stratified for cytoplasmic, nuclear and extent of 
staining, cytoplasmic and nuclear CK2 staining showed a significant positive 
correlation (r=0.36 with p= 0.04; r=0.50 with p<0.001 respectively) with age (the 
only established risk factor for the prostate cancer).  NFkB was also found to be 
related with age of the patient. Total and cytoplasmic staining for NFkB had no 
significant relation (p=0.1 and p=0.8 respectively), while nuclear NFkB showed a 
significant positive (r=0.44, p= 0.01) correlation with increasing age. No 
association was found between the age and Ki67 expression (p=0.9), table 6B. 
4.9.2 Gleason Score 
Nonparametric χ2 test was used to analyze the association of all three 
markers with Gleason score (stage of the prostate cancer) of patients.  Total and 
 cytoplasmic CK2 does not show any significant association with the Gleason 
score of patients. But nuclear staining showed a significant (χ2 test p<0.001) 
association with the increasing grade of the disease. Data was stratified in to two 
groups group. Group one was Gleason score ≤ 6 and the other group was Gleason 
score ≥ 7.  Further samples were assigned to each group on the basis of nuclear 
staining present (Nu+) or nuclear staining absent (Nu-).  Only the nuclear NFkB 
staining showed a significant correlation with the Gleason score of patients with χ2 
test p< 0.00. Again data was stratified on the basis of nuclear stain with +1 score 
and nuclear stain+2 or more score, in the two groups of Gleason score mentioned 
above. Other parameters (cytoplasmic and total NFkB) were not significantly 
associated with Gleason score. Again Ki67 did not show significant correlation 
with Gleason score (χ2 test, p=0.4) table 6B. 
4.9.3 Lymphovascular/Perinural Invasion 
No significant association or correlation was found between CK2α, NFkB 
and Ki67 and lymphovascular and perinural invasion. Even after stratification of 
data into nuclear, cytoplasmic, extent of staining and total values. No significant 
inference could be drawn between these parameters. 
4.9.4 Percentage of Prostatic Tissue Involved 
Data for percentage of prostatic tissue involved was divided into two 
groups. ≤60% of tissue involved and the other group was ≥70% of prostatic tissue 
involved. Nuclear staining for CK2 was assigned to each group on the presences 
of Nu+ and or absence of Nu-. Nuclear staining for NFkB was also divided into 
two groups and then assigned to each group of prostatic tissue involved. Two 
 groups for NFkB nuclear stain was Nu+1 and NU+2 and above. Only CK2 
nuclear stain was correlated significantly with the percentage of prostatic tissue 
involved (χ2, p=0.00). No other parameter of any of the three variables showed 
any significant relationship table 6B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 6A: Descriptive statistics of variables (CK2α, NFkB and Ki67) and 
clinicopathological features 
 
 
Observations N Minimum Maximum Mean Std. Deviation 
GleasonScore 30 5.00 9.00 7.13 1.25 
Age 30 28.00 90.00 69.60 11.96 
CK2 Nuclear 30 .00 3.00 1.33 .96 
CK2 Cytoplasmic 30 1.00 3.00 1.67 .61 
CK2 Extent 30 1.00 4.00 2.23 1.00 
CK2 Total 30 2.00 9.00 5.23 1.94 
NFkB Nuclear 30 1.00 4.00 1.93 .944 
NFkB Cytoplasmic 30 1.00 3.00 2.43 .73 
NFkB Extent 30 1.00 4.00 2.37 .96 
NFkB Total 30 3.00 10.00 6.73 1.89 
Ki67 30 3.00 47.00 20.40 12.89 
 
Table 6B: Association of CK2α, NFkB and Ki67 with the clinicopathological 
parameters of adenocarcinoma patients. * shows significant association with  
P ≤ 0.05  
 Age Gleason Score % of prostatic 
tissue involved 
CK2 Total r=0.27 P=0.1 P=0.4 P=0.3 
CK2 Nuclear r=0.50 P=0.00
* χ2 p= 0.00*  P=0.00* 
CK2 Cytoplasmic r=0.36 P=0.04
* 
P=0.5 P=0.19 
NFkB Total r=0.29 P=0.1 P=0.9
 
P=0.13 
NFkB Nuclear r=0.44 P=0.01
*
 χ2 p= 0.00* P=0.20 
NFkB 
Cytoplasmic 
r=0.02 P=0.8 P=0.7
 
P=0.4 
Ki67 r=0.02 P=0.9 P=0.4 P=0.9 
 
 4.10 Comparison of CK2α, NFkB and Ki67 expression between 
patients of Adenocarcinoma of prostate and BPH 
All the three variables were detectable in both adenocarcinoma and BPH 
patients. CK2 was detectable in both nuclear and cytoplasmic compartments of the 
cell in both groups, figure 18. The comparison of means showed an increase in 
overall expression of total CK2 (p<0.001) in cancer group. Data was stratified in 
cytoplasmic, nuclear and extent of staining. Nuclear and extent of staining showed 
a significant over expression of CK2 in CA as compared to BPH (p=0.04 & 
p<0.001 respectively). Mean cytoplasmic CK2 was also higher in cancer group 
but the difference did not show any statistical significance (p=0.07), figure 19.  
Both BPH and prostate cancer patients showed over expression of NFkB 
in cytoplasmic as well as nuclear compartment of the cells figure 20. Analysis of 
their means by t-test showed significant over expression of NFkb in 
adenocarcinoma as compared to BPH. All the three sub set of data was 
significantly different in the two groups. P-values observed were, NFkB nuclear 
(p=0.04), cytoplasmic NFkB (p=0.03), extent of staining (p=0.01) and total NFkB 
(p<0.001), figure 21. 
Immunohistochemistry showed a marked difference in the expression 
pattern of Ki67 between prostate adenocarcinoma and BPH samples. Ki67 was 
only sparsely detectable in BPH patients as compared to densely stained 
adenocarcinoma cells, figure 22A. Comparison of their means showed a highly 
significant difference between two groups (p<0.001), figure 23. 
 
 A 
 
B 
 
Figure 18: Comparison of expression pattern of CK2 between prostate 
adenocarcinoma and BPH samples. A. BPH tissue showing mostly cytoplasmic 
staining of CK2. B. Prostate carcinoma tissue with prominent cytoplasmic as well 
as nuclear CK2 staining.  
  
 
Figure 19: Comparison of means of CK2 staining scores by independent t-test 
between prostate cancer and BPH. Values are represented as mean ± SEM. 
*p≤0.05 is considered significant. The entire sub set of data (nuclear, cytoplasmic 
and extent of staining) were over expressed in cancer (CA) patients as compared 
to BPH. Although cytoplasmic increase did not show any statistical significances, 
rest of the sub groups were significantly different. Nuclear staining p=0.04* and 
p<0.001** for both total CK2 stain and extent of staining. 
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Figure 20:  Comparison of expression pattern of NFkB between prostate 
adenocarcinoma and BPH samples. A. BPH tissue showing mostly cytoplasmic 
staining of NFkB. B. Prostate carcinoma tissue with prominent cytoplasmic as 
well as nuclear NFkB staining. 
 
  
 
Figure 21: Comparison of means of NFkB by independent t-test between 
prostate cancer and BPH group. Values are represented as mean ± SEM. *p≤0.05 
is considered significant. The entire sub set of data (nuclear, cytoplasmic and 
extent of staining) were significantly over expressed in CA patients as compared 
to BPH. Total NFkb staining p<0.001**, Nuclear staining p=0.04*, cytoplamsic 
stain p=0.03* and p=0.01* for extent of staining. 
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Figure 22:  Comparison of expression pattern of Ki67 between prostate 
adenocarcinoma and BPH samples. A. BPH tissue showing mostly cytoplasmic 
staining of Ki67. B. Prostate carcinoma tissue with prominent nuclear Ki67 
staining. 
 
 
  
 
 
 
Figure 23: Comparison of change in percentage of means of Ki67 by 
independent t-test between prostate cancer and BPH group. Values are represented 
as percentage of mean ± SEM. *p≤0.05 is considered significant. Nuclear staining 
was significantly over expressed in CA patients as compared to BPH p=0.00** 
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 4.11 Collaborative role of CK2, NFkB and ki67 in pathogenesis of 
prostate cancer 
Regression analysis was carried out with in the adenocarcinoma samples to 
find association between the three variables under investigation. Analysis showed 
a significant and positive correlation between the expressions pattern of CK2 and 
NFkB. Total CK2 was strongly associated with total NFkb (r=0.62, p<0.001), 
table 7 A. When data was split into nuclear and cytoplasmic fractions, only 
nuclear fraction of CK2 and NFkB showed a significant positive correlation 
(r=0.44, p=0.01), table 7 B. Cytoplasmic fraction although was associated to 
moderate extent (r=0.33) but no significant association could be drawn between 
the two factors (p=0.06). CK2 is only weakly associated with the Ki67 (r=0.20), 
table 8. No significant association was found between the two variables (p=0.2). 
Similarly these three variables were analyzed in the BPH group as well. 
CK2 total and NFkB total score was correlated (r=0.61, p=0.04) table 9 A. When 
data was stratified in to nuclear and cytoplasmic staining, two sub set did not 
show any significant association with each other (r=0.42, p=0.1 & r=0.20, p=0.5 
respectively) table 9 B & C.  Total CK2 and Ki67 did not show correlation.  
 
 
 
 
 Table 7A: Regression analysis of CK2 total staining with NFkB total 
staining within the adenocarcinoma of prostate group. Regression analysis 
shows a strong positive relationship between the two variables in the pathogenesis 
of prostate cancer. ** shows highly significant results 
     
      Regression Statistics 
    
Multiple R 0.62 
     
R Square 0.40 
    
Adjusted R 
Square 0.37 
     
Standard Error 1.54 
    
Observations 30 
    
       
 
ANOVA 
     
  
Degree of 
freedom 
(df) 
Sum of 
Squares 
(SS) 
Mean 
Square 
(MS) F-Test (F) 
Significance 
F 
Regression 1 43.04 43.05 18.17 0.0001** 
Residual 28 66.32 2.37 
  Total 29 109.37     
      
  Coefficients 
Standard 
Error t Stat P-value 
 Intercept 0.90 1.05 0.85 0.40 
 CK2 total 0.64 0.15 4.26 0.0001** 
  
 
 
 
 Table 7B: Regression analysis of nuclear CK2 stain with nuclear NFkB 
staining within the adenocarcinoma of prostate group. Regression analysis 
shows a strong positive relationship between the two variables in the pathogenesis 
of prostate cancer. * shows significant results 
     
     Regression Statistics 
    Multiple R 0.44 
     
R Square 0.20 
     
Adjusted R 
Square 0.17 
     
Standard Error 0.91 
     
Observations 30 
    
      
ANOVA 
     
  df SS MS F 
Significance 
F 
Regression 1 5.26 5.26 6.88 0.01* 
Residual 28 21.40 0.76 
  Total 29 26.67       
      
  Coefficients 
Standard 
Error t Stat P-value 
 Intercept 0.46 0.37 1.25 0.22 
 CK2 Nuclear 0.45 0.17 2.62        0.01* 
  
 
 
 
 Table 8:  Regression analysis of total CK2 staining with Ki67 staining within 
the adenocarcinoma of prostate group. Regression analysis shows no 
significant relationship between the two variables in the pathogenesis of prostate 
cancer.  
 
Regression Statistics 
    Multiple R 0.21 
     
R Square 0.04 
     
Adjusted R 
Square 0.01 
     
Standard Error 1.93 
     
Observations 30 
    
      
ANOVA 
     
  df SS MS F 
Significanc
e F 
Regression 1 4.81 4.81 1.288 0.27 
Residual 28 104.56 3.73 
  Total 29 109.37       
      
  
Coefficient
s 
Standard 
Error t Stat P-value 
 Intercept 4.59 0.67 6.86 1.85E-07 
 Total CK2 0.03 0.03 1.13 0.27 
  
 
 
 
 Table 9A: Regression analysis of CK2 total staining with NFkB total 
staining within the BPH group. Regression analysis shows a positive 
relationship between the two variables. *shows significant results 
 
Regression Statistics 
    Multiple R 0.61 
     
R Square 0.37 
     
Adjusted R 
Square 0.30 
     
Standard Error 0.87 
     
Observations 11 
    
      
ANOVA 
     
  df SS MS F 
Significanc
e F 
Regression 1 4.08 4.08 5.38 0.04* 
Residual 9 6.82 0.76 
  Total 10 10.90       
      
  
Coefficient
s 
Standard 
Error t Stat P-value 
 Intercept 1.11 0.82 1.36 0.21 
 X Variable 1 0.38 0.16 2.32 0.04* 
  
 
 
 
 Table 9B: Regression analysis of CK2 nuclear staining with NFkB nuclear 
staining within the BPH group. Regression analysis shows no significant results 
between two variables 
 
Regression Statistics 
    Multiple R 0.43 
     
R Square 0.18 
     
Adjusted R 
Square 0.09 
     
Standard Error 0.88 
     
Observations 11 
    
      
ANOVA 
     
  df SS MS F 
Significance 
F 
Regression 1 1.54 1.55 1.99 0.19 
Residual 9 7 0.78 
  Total 10 8.54       
      
      
  Coefficients 
Standard 
Error t Stat 
P-
value 
 Intercept -1.1E-16 0.52 -2.1E-16 1 
 CK2 Nuclear 0.5 0.35 1.40 0.19 
  
 
 
 Table 9C: Regression analysis of CK2 cytoplasmic staining with NFkB 
cytoplasmic staining within the BPH group. Regression analysis shows no 
significant results between two variables 
 
Regression Statistics 
    Multiple R 0.21 
     
R Square 0.04 
     
Adjusted R 
Square -0.06 
     
Standard Error 0.67 
     
Observations 11 
    
      
ANOVA 
     
  df SS MS F 
Significanc
e F 
Regression 1 0.18 0.18 0.41 0.54 
Residual 9 4 0.44 
  Total 10 4.18       
      
  
Coefficient
s 
Standard 
Error t Stat P-value 
 Intercept 1.75 0.77 2.26 0.05 
 X Variable 1 -0.25 0.39 -0.64 0.53 
  
 
 
 
 
 4.12 Clinocopathlogical Features of Breast Cancer Patients 
Table 10A represents the observations obtained from the data base of 
patients at department of histopathology at the AFIP. All the clinical and 
pathological grades were assigned by the classified histopathologist. 
4.13 Expression Analysis of CK2, NFkB and Ki67 in Breast cancer 
tissue specimens.  
 Hematoxylin and eosin (H&E) staining was carried on every sample to 
determine the pathological stage of the tumor, figure 24 is the representative H&E 
figure. To determine the expression pattern (cytoplasmic and nuclear) of CK2, 
NFkB and Ki67 immunohistochemistry was carried out. Staining was scored. For 
CK2 range of score is from 0-3+ for nuclear and cytoplasmic stain. Sum of these 
readings is the total score for CK2, figure 25(A, B and C). For NFkB scoring 
range is 0-4+ for nuclear and cytoplasmic staining and sum represents the total 
NFkB value, figure 26(A, B & C). Ki67 was scored by counting 30 nuclei at five 
different randomly picked representative sections within the same tissue 
specimen. Out of these 30, nuclei stained positively were counted in each section.  
Thus over all totals of 150 nuclei were counted per specimen. Percentage of 
positive nuclei was calculated for analysis, figure 27 (A, B & C). 
 
 
 
 
 Table 10A: Clinicopathological features of patients with Invasive ductal 
carcinoma of breast. Values are represented as mean for age, size of tumor and 
Nottingham prognostic index. Actual values are given for skin 
involvement/lymphovascular invasion and Lymphnode Metastasis. 
 
 
Mean Age                                                                       50.0 (29-80) years 
Nottingham prognostic index                                                         5.4 (3-8) 
3-5                                                                                                  15 (50%) 
6-9                                                                                                  15 (50)% 
Lymphnode Metastasis 
Present                                                                                            19 (63.3%) 
Absent                                                                                             11(36.7%) 
Skin involvement/lymphovascular Invasion 
Present                                                                                              21(70%) 
Absent                                                                                                9 (30%) 
Size of Tumor cm
3                       
                                                 8.9 cm
3
 (3-25.5) 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 24: Representative H&E staining of tumor tissue, to determine the 
histological parameters of the disease. 
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Figure 25: Immunohistochemical Expression pattern of CK2. Breast 
cancer tissue samples were stained using the DAB method to determine the 
expression pattern of CK2. Acquisition of brown color shows the positive 
staining. CK2 was scored in both nuclear and cytoplasmic compartment. Figure A 
shows nuclear 1+ staining with 2+ cytoplasmic. Figure B shows the positive 
staining with scores as nuclei 2+ and cytoplasmic 2+ this makes the total CK2 
score of 4+. Figure C scoring is nuclei 3+, cytoplasmic 1+.       
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Figure 26: Immunohistochemical Expression pattern of NFkB. Breast 
cancer tissue samples were stained using the DAB method to determine the 
expression pattern of NFkB. Acquisition of brown color shows the positive 
staining. NFkB was scored in both nuclear and cytoplasmic compartment. Scoring 
range is 0-4+. Figure A shows 1+ nuclear staining with 0 cytoplasmic staining 
score. Figure B shows the positive staining with scores as nuclei 3+, cytoplasmic 
1+ this makes the total NFkB score of 4+. Figure C scoring is nuclei 4+, 
cytoplasmic 1+.  
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Figure 27: Immunohistochemical Expression pattern of Ki67. Breast 
carcinoma tissue samples were stained using the DAB method to determine the 
expression pattern of Ki67. Acquisition of brown color shows the positive 
staining. Ki67 was scored by counting 30 nuclei at five different randomly picked 
representative sections within the same tissue specimen. Out of these 30, nuclei 
stained positively were counted in each section.  Thus over all totals of 150 nuclei 
were counted per specimen. Percentage of positive nuclei was calculated for 
analysis.  A result of less than 10% is considered low, 10-20% borderline, and 
high if more than 20%. A. shows the ki67 score of < 10% B. cells with 10-20% 
positive Ki67 nuclei. C. shows the > 20% staining for Ki67.           
 4.14 Assessing role of CK2 in prognosis of disease; Correlation of 
CK2, NFkB and Ki67 with clinicopathological features and stage 
of breast cancer   
Immunohistochemical analysis was carried to determine the relationship of 
CK2α, NFkB and Ki67 expression with clinicopathological features (Nottingham 
prognostic index, lymphovascular and perinural invasion and percentage of 
prostatic tissue involved) and lymph node metastais. Table 10B shows the 
descriptive statistics for all the variables. CK2 and NFkB were over expressed in 
all the tissues examined.  
4.14.1 Nottingham prognostic index 
Nonparametric χ2 test was used to analyze the association of all three 
markers with Nottingham prognostic index of patients.  Total CK2 was 
significantly associated with the increasing prognostic index (p=0.01). Data was 
split into cytoplasmic and nuclear staining scores. Cytoplasmic component did not 
show any significant association with Nottingham prognostic index of patients. 
But nuclear staining showed a significant (χ2 test p<0.001) association with the 
increasing Nottingham prognostic index of patients. Data was stratified in to two 
groups group. Group one was with Nottingham prognostic index 3-5 and the other 
group was Nottingham prognostic index 6-9.  Further samples were assigned to 
each group on the basis of nuclear staining present Nu0/1+ or nuclear staining ≥2 
Nu+2/+3.  Ki67 was divided into < 10%, 10-20% and > 20% of staining. Ki67 did 
not show significant correlation with Nottingham prognostic index, table 11. 
 
 4.14.2 Lymph node metastasis 
To assess the role of CK2 and associated factors (NFkB and Ki67) with 
the metastasis of breast cancer, χ2 test was carried out. Statistics showed a strong 
positive association of CK2 total with lymph node metastasis (χ2 p<0.001). Both 
cytoplasmic and nuclear stain was also found to be significantly related to 
metastasis of disease (χ2 p=0.02 and p=0.00 respectively). No significant 
association was found between any of the NFkb staining pattern (Nuclear, 
cytoplasmic and total) with disease metastasis. Ki67 did not show significant 
association with lymph node metastasis, table 11 
No significant association or correlation was found between CK2α, NFkB 
and Ki67 with lymphovascular and skin involvement. Even after stratification of 
data into nuclear and cytoplasmic staining. No significant inference could be 
drawn between these parameters. 
Regression analysis was carried out to determine the relationship between 
CK2, NFkB and Ki67 and size of the tumor in cm
3
. None of the variable showed 
any significant association with the size of the tumor, table 11. 
 
 
 
 
 
 Table 10B: Descriptive statistics of variables (CK2α, NFkB and Ki67) and 
clinicopathological features 
 
 
 
N Minimum Maximum Mean 
Std. 
Deviation 
Nottingham prognostic 
index 
30 3.00 7.70 5.4 1.4 
 
Size of tumor 
30 1.40 25.50 8.9 5.6 
 
CK2Nuclear 
30 1.00 3.00 1.7 0.78 
 
CK2Cytoplasmic 
30 .00 2.00 0.9 0.76 
 
CK2Total 
30 1.00 5.00 2.6 1.3 
 
NFkB Nuclear 
30 .00 3.00 1.9 0.9 
 
NFkB Cytoplasmic 
30 1.00 3.00 1.7 0.8 
 
NFkB Total 
30 1.00 6.00 3.7 1.5 
 
Ki67 
30 5.00 43.00 16.0 10.9 
 
 
 
 
 
 
 Table 11: Association of CK2α, NFkB and Ki67 with the clinicopathological 
parameters of Breast Cancer patients. * shows significant association with  
P ≤ 0.05, **p=0.01 
 
 Nottingham 
prognostic index  
Lymphovascular/ 
Skin involvement 
Size of 
Tumor 
Lymph 
Node 
Metastasis 
CK2 Total 
 
                         
p=0.01* 
                        
p=0.2 P=0.6 P<0.00** 
CK2 Nuclear 
 
                    
p=0.02*
                         
p=0.1 P=0.4 P<0.00** 
CK2 
Cytoplasmic 
 
                          
p=0.1
                         
p=0.3 P=0.9 P=0.02* 
NFkB Total 
 
                    
p=0.01* 
                        
p=0.2
 
P=0.7 P=0.1 
NFkB Nuclear 
 
                    
p=0.04* 
                        
p=0.5
 
P=0.6 P=0.2 
NFkB 
Cytoplasmic 
 
                           
p=0.4 
                        
p=0.8
 
P=0.9 P=0.1 
Ki67 
 
                            
p=0.1 
                        
p=0.1 P=0.8 P=0.3 
 
 
 
 
 
 4.15 Association of CK2, NFkB and ki67 in pathogenesis of Breast 
Carcinoma 
Regression analysis was carried out within the carcinoma tissue samples to 
find association between the three variables under investigation. Analysis showed 
a significant and positive correlation between the expressions pattern of CK2 and 
NFkB. Total CK2 was significantly associated with total NFkb (r=0.43, p=0.01), 
table 12 A. When data was split into nuclear and cytoplasmic fractions, only 
nuclear fraction of CK2 and NFkB showed a significant positive correlation 
(r=0.39, p=0.03), table 12 B. Cytoplasmic fraction although was associated to 
moderate extent (r=0.33) but no significant association could be drawn between 
the two factors (p=0.07). CK2 is only weakly correlated with the Ki67 (r=0.21), 
table 13. No significant association was found between the two variables (p=0.2). 
 
 
 
 
 
 
 
 
 Table 12A: Regression analysis of CK2 total staining with NFkB total 
staining within the breast carcinoma group. Regression analysis shows a strong 
positive relationship between the two variables in the pathogenesis of cancer. ** 
shows highly significant results 
 
Regression Statistics 
    Multiple R 0.43 
     
R Square 0.19 
     
Adjusted R 
Square 0.16 
     
Standard Error 1.39 
     
Observations 30 
    
      ANOVA 
     
  Df SS MS F 
Significance 
F 
Regression 1 12.72 12.73 6.57 0.01** 
Residual 28 54.24 1.94 
  Total 29 66.97       
      
  Coefficients 
Standard 
Error t Stat P-value 
 Intercept 2.29 0.58 3.93 0.00 
 CK2 Total 0.50 0.19 2.56 0.01** 
 
       
 
 
  
 Table 12B: Regression analysis of nuclear CK2 staining with nuclear NFkB 
staining scores within the breast cancer group. Regression analysis shows a 
positive relationship between the two variables in the pathogenesis of breast 
scancer. * shows highly significant results 
 
Regression Statistics 
    Multiple R 0.39 
     
R Square 0.15 
     
Adjusted R 
Square 0.12 
     
Standard Error 0.86 
     
Observations 30 
    
      ANOVA 
     
  Df SS MS F 
Significance 
F 
Regression 1 3.76 3.76 5.03 0.03* 
Residual 28 20.93 0.74 
  Total 29 24.7       
      
  Coefficients 
Standard 
Error t Stat P-value 
 Intercept 1.10 0.39 2.85 0.00 
 X Variable 1 0.46 0.20 2.2 0.03* 
  
 
 
 Table 13: Regression analysis of CK2 staining with Ki67 staining scores 
within the breast cancer group. No significant relationship was found between 
the two variables in the pathogenesis of breast cancer 
 
Regression Statistics 
    Multiple R 0.21 
     
R Square 0.04 
     
Adjusted R 
Square 0.01 
     
Standard Error 7.25 
     
Observations 30 
    
      ANOVA 
     
  Df SS MS F 
Significance 
F 
Regression 1 69.86 69.9 1.323 0.26 
Residual 28 1471.4 52.55 
  Total 29 1541.2       
      
  Coefficients 
Standard 
Error t Stat P-value 
 Intercept 7.57 3.03 2.49 0.01 
 CK2  1.19 1.04 1.15 0.26 
  
 
 
 
 
 Chapter 5 
Discussion 
Several factors and pathways that may play a role in the apoptotic process 
triggered by the inhibition of CK2 have been examined, including IAPs, Bcl 
family proteins, ROS, and caspases (Wang et al., 2001, Ahmad et al., 2006, Tapia 
et al., 2006, Wang et al., 2008, Duncan et al., 2011, Ponce et al., 2011, Turowec et 
al., 2011). These activities point to the temporal progression of apoptotic signaling 
that occurs in response to inhibition or downregulation of CK2. However, the 
nature of the primary trigger(s) for the initiation of apoptotic signaling has been 
unclear.  
Present study reports a novel observation that suggests a potential 
mechanism for the initiation and progression of apoptosis after CK2 inhibition. 
We have shown that when cells are treated with the relatively specific CK2 
inhibitor TBB the initiation of cell survival loss occurs between 4 to 6 h following 
inhibitor treatment, implying the existence of events preceding this time frame. 
Accordingly, we have found that under the present experimental conditions, loss 
of Δψm is apparent as early as 2 h following treatment with TBB. Further, it 
appears that this alteration in mitochondrial physiology involves changes in the 
permeability transition pore as well as Ca
2+
 dynamics since prior treatment with 
the specific Ca2+ chelator BAPTA blocked the change in membrane permeability 
and Δψm. 
Previously, it was also suggested that production of H2O2 may be the 
proximal trigger for initiation of apoptosis on downregulation or inhibition of 
 CK2 in prostate cancer cells; however, this event occurred at around 4 to 6 h 
following CK2 inhibition (16). If production of ROS preceded changes in Δψm in 
these cells, then treatment of cells with a ROS scavenger should block the changes 
in Δψm. However here we report that prior treatment of cells with the ROS 
scavenger catalase did not influence the rapid changes in Δψm caused by CK2 
inhibition. This argues against H2O2 being the initiator of apoptotic signaling in 
response to CK2 inhibition in prostate cancer cells. Additional analysis of the 
temporal response for several of the apoptotic signals on inhibition of CK2 
suggested changes in Bid to occur at 4 to 6 h while other signals of apoptosis such 
as the cytosolic appearance of cytochrome c, activation of caspases, and 
production of lamin A/C cleavage products to be among the later events. Finally, 
the JC-1 microscopy implies a direct role for CK2 activity in maintaining the 
mitochondrial membrane potential. 
Based on these various observations, we propose that one of the earliest 
events in response to CK2 inhibition in the cells is altered Ca2+ flux into 
mitochondria which promotes a change in mitochondrial permeability and loss of 
mitochondrial membrane potential. These early changes are likely to represent the 
“point of no return” for cell fate decision so that loss of survival begins at 4 to 6 h. 
Associated with this time point are changes in Bid translocation as evidenced by 
reduction of cytosolic full length Bid (as early as 4 to 6 h) and production of 
H2O2 (around 4 to 6 h) followed by the previously described changes in the Bcl 
family proteins and activation of caspases which represent terminal phase events 
leading to cell death. 
 One of the most important clinical challenges faced by the biomedical 
sciences today is the existing inability to efficiently differentiate between the 
indolent forms of cancer with aggressive tumors phenotype. This deficiency of 
information about prognostic markers led to „„overtreatment‟‟ of patients, thus 
diluting the benefits of treatment options associated with the advancement in 
technology (Shen and Abate-Shen, 2010). 
CK2 has been long known as to be associated with the normal and 
malignant proliferative process of cells. CK2 levels in the cancer specimens relate 
to the pathological status of the cancer and CK2 could serve as a potential 
prognostic factor (Faust et al., 1996, Gapany et al., 1995, Giusiano et al., 2011, 
Laramas et al., 2007). However, it is also know that CK2 is elevated in benign 
proliferative conditions as well (Yenice et al., 1994). Thus the present study was 
designed to find out potential additional factors associated with CK2 that works in 
collaboration towards the pathogenesis of cancer. 
Immunohistochemical analysis of CK2, NFkB and Ki67 showed that all 
these factors were significantly over expressed in the cancer tissues as compared 
to BPH. Our results demonstrate that CK2 and NFkB are associated with many of 
the pathological features of the cancer. 
In prostate cancer specimens nuclear staining for CK2 and NFkB was 
significantly associated with Gleason score, percentage of prostatic tissue 
involved and age of the patient. Total and cytoplasmic staining was also elevated 
but did not show any association with the grade of the disease, except cytoplasmic 
CK2 staining was significantly associated with age of patients. Our findings are in 
 line with the previous studies which show that it is the nuclear CK2 which plays 
the crucial role in the pathogenesis and progression of disease. Literature also 
support the same pattern of expression for NFkB (Ahmed, 1994, Ahmed, 1999, 
Ahmed et al., 1993, Laramas et al., 2007, Lessard et al., 2003). Ki67 did not show 
any significant association with any of the prognostic or pathological state of 
prostate cancer. This result has a limited support from studies of other labs. There 
are few studies which report relevance of Ki67 with Gleason score only and not 
with any of the pathological parameter e.g. (Sulik et al., 2011). The plausible 
reason that we could not determine the any association of Ki67 could be the fact 
that we had limited number of samples. We believe that increasing the number the 
total number of observation will make up for this discrepancy. Thus present study 
supports the notion that there is an overall increase in CK2 and NFkB expression 
in benign as well as malignant states but it is the nuclear staining which is 
associated with the poor prognosis of the disease. 
Comparison of means of CK2, NFkB and Ki67 between the BPH and 
cancer tissue showed that over all there was a marked and significant increase in 
staining for CK2, NFkB and Ki67. Data was stratified in to nuclear and 
cytoplasmic staining scores. Total as well as nuclear staining CK2 was 
significantly over expressed in cancer tissue specimens. Although cytoplasmic 
staining was also elevated in cancer tissue as compared to BPH but there was no 
significant difference between the two. Again our results were in line with the 
previous data which reports that CK2 is over expressed in benign as well as 
malignant proliferative states (Yenice et al., 1994) and CK2 not only predict the 
proliferative state but also reflects the level and or state of the disease (Ahmed et 
 al., 2000, Faust and Montenarh, 2000, Faust et al., 1996). Finding of present study 
that all the components of NFkB staining is significantly over expressed in the 
prostate cancer is well supported and documented by the studies from other labs 
(Lessard et al., 2005, Lessard et al., 2003, Shukla et al., 2004). Present study 
strengths the case in favor of NFkB as the potential marker in the prognosis of 
prostate cancer. Our finding is also in line with the previous data available on over 
expression of Ki67 in malignant conditions (Fisher et al., 2013, Sulik et al., 2011).  
There have been tremendous independent efforts in evaluating various 
factors that can serve as an efficient prognostic marker for prostate cancer. Many 
studies have reported multiple proteins that can serve the purpose but in most if 
not all the instances all these factors are so intricately related to many other 
signaling proteins that it has become difficult to single out any of these proteins 
that can fulfill the job. To add to this complex interplay, most of these signaling 
molecules also play a vital part in the normal as well as benign proliferative 
conditions.  Thus making it more difficult to determine and differentiate between 
the indolent and aggressive nature of proliferation. Keeping in view the above 
mentioned challenges, present study was designed to test the hypothesis that 
coupling of multiple factors might be better in predicting prognosis of prostate 
cancer. We also proposed that these combinational studies will give better 
understanding about the pathogenesis of the cancer.  
Keeping in view the above mentioned concept, present study reports for 
the first time, possible collaborative role of CK2 and NFkB in the pathogenesis of 
prostate cancer as explained as under:- 
 One of the main findings of present is study is that CK2 and NFkB are 
strongly associated with each other in pathogenesis of prostate cancer. All the 
components of staining (nuclear, cytoplasmic and total) were significantly 
associated between the two factors. The important aspect of this association is the 
fact that BPH does not show this association. Although total scores of CK2 and 
NFkB were related in BPH as well but when data was stratified into nuclear and 
cytoplasmic staining scores, this association was lost. As we and other studies 
(Ahmed et al., 1993, Faust et al., 1996, Laramas et al., 2007, Lessard et al., 2005, 
Lessard et al., 2003, Trembley et al., 2010a) have reported that nuclear staining 
for CK2 and NFkB is critical in  determination of the state of prostate cancer, thus 
we also reports that it is the association between increasing nuclear expression of 
CK2 and NFkB which dictates changes from benign to malignant phenotype. 
Absence of this association in BPH strengths our proposal. We carried out the 
analysis for this association between CK2 and Ki67 as well. Results shows that 
these two factors are only weakly associated with each other and there does not 
exsists any significant relationship between CK2 and Ki67 in the development of 
prostate cancer carcinoma. 
Keeping in view the fact that CK2 has been observed to be distinctively 
over expressed in all the cancer studied so far (Guerra and Issinger, 1999, Tawfic 
et al., 2001), we tested weather the association of CK2 and NFkB that we have 
observed in prostate cancer also exists in any other cancer. These studies will 
point towards the universality of the collaborative role of CK2 and NFkB in 
pathogenesis of cancer. 
 Similar series of experiments were carried out in breast cancer tissue 
samples. Results were similar to those observed in prostate cancer study.  
Our findings that CK2, NFkB and Ki67 are over expressed in breast cancer 
are in line with the previous findings (Inwald et al., 2013, Landesman-Bollag et 
al., 2001a, Nishimura et al., 2010, Romieu-Mourez et al., 2002). Total and nuclear 
CK2 and NFkB are strongly associated with the Nottingham prognostic index of 
breast cancer specimens; CK2 over expression was significantly associated with 
lymph node metastasis. All the staining scores (nuclear, cytoplasmic and total) 
were significantly related with metastatic state. NFkB and Ki67 did not show any 
significant association with lymphnode metastasis. Age, lymphovascular invasion, 
skin involvement and size of tumor were found not to be related with CK2, NFkB 
and Ki67 expression patteren.  
Regression analysis of CK2 and NFkB shows that, both these factors are 
associated in the pathogenesis of breast cancer. Total and nuclear staining scores 
were significantly related to each other in development of malignant phenotype. 
Cytoplasmic staining of CK2 and Ki67 did not show any significant association. 
Our results are supported by the previous studies carried out in breast cancer cell 
lines as well as western blot analysis of nuclear fractions of human breast cancer 
specimens (Landesman-Bollag et al., 2001a, Landesman-Bollag et al., 2001b, 
Romieu-Mourez et al., 2002). Thus our results further enhance the previous 
knowledge that NFkB is activated by CK2 and we report that both these factors 
work in collaboration in development of breast cancer. 
 CK2 and Ki67although were over expressed in breast malignancy but did 
not show any significant association with each other in pathogenesis of disease. 
Apparently the underlying mechanism associated with over expression of these 
two factors follows different signaling pathways. 
In summary, present study significantly adds to and improves our 
knowledge of basic biology of the CK2. Further it has provided a better 
understand of the CK2 signaling in pathogenesis of cancer. While it has been well 
documented that inhibition or downregulation of CK2 promotes apoptosis in cells, 
the underlying triggering mechanism that initiated the mitochondrial apoptotic 
signaling was not well understood. Our observations that downregulation of CK2 
evokes an early change in mitochondrial Ca2+ dynamics associated with altered 
permeability and loss of Δψm provide a novel mechanism of how CK2 may be 
involved in regulation of cell apoptosis. 
Here we report the collaborative role of CK2 and NFkB in the 
pathogenesis of the prostate as well as breast cancer. We also report that CK2 and 
Ki67 work independent of each other in disease condition.  Similar kind of results 
in the two forms of cancer suggests the association between the CK2 and NFkB 
may be the common underlying mechanism involved in the development of most 
of the cancers. Thus the two factors in combination could as a better prognostic 
marker as well as potent target for cancer therapy.  
 
 
 
 Chapter 6 
Conclusions 
 Loss of Δψm may be a primary trigger for apoptotic signaling resulting 
from CK2 inhibition. 
 Alterations in Ca2+ signaling may be involved in the CK2 mediated 
regulation of Δψm 
 Nuclear expression of CK2α and NFkB are strongly correlated with each 
other and may work in collaboration in pathogenesis of cancer. 
 Combination of CK2 and NFkB might serve as a better prognostic marker 
for prognosis of cancer 
 
 
 
 
 
 
 
 
 
 
 Limitations of present study and future prospects 
Sample size of present study is limited. In future such studies should be 
carried out at larger scale. Although this sample size is enough to study the basic 
biological mechanisms but observation about the prognosis value of markers need 
to be tested in larger more diverse population.  Breast cancer study is just the 
supportive portion of the main study. Breast cancer is a very diverse disease and a 
specialty in itself. Thus independent large study should be carried out on breast 
cancer samples taking in to account all the pathological features of disease. 
CK2 is known to have more than 300 potential substrates. Additional 
factors should also be tested in relation to CK2 in pathogenesis of disease.  
The mechanism of change(s) in the Ca2+ dynamics in mitochondria in 
response to downregulation of CK2 needs further studies. In addition to 
mitochondria, other organelles like endoplasmic reticulum and Golgi apparatus 
should also be involved in studies addressing CK2 dynamics. 
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 Appendices 
 
 
 
 
 Consent Forum 
 
I ________________________ (patient‟s name) is fully aware of the study 
purpose and protocol entitled “CK2 as suppressor of Apoptosis and Potential 
Prognostic Marker for Cancer”. I volunteer to participate in this research study. I 
understand that I will receive a copy of this form. I voluntarily choose to 
participate, but I understand that my consent does not take away any legal rights 
in the case of negligence or other legal fault of anyone who is involved in this 
study. I further understand that nothing in this consent form is intended to replace 
any applicable Federal, state, or local laws. 
 
Participant Name (Printed or Typed): 
Date:  
 
 
Participant Signature: 
Date:  
 
 
 
Principal Investigator Signature:    Signature of Person 
Obtaining Consent: 
Date:       Date  
 
 
 
